UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

x☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, ~~2020~~2021

£☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________.

Commission File Number: 001-38459

SURFACE ONCOLOGY, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware			46-5543980
( State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
50 Hampshire Street, 8th Floor Cambridge, MA			02139
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (617) 714-4096

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common stock, $0.0001	SURF	The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes S☒ No £☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes S☒ No £☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	£☐	Accelerated filer	£☐
Non-accelerated filer	S☒	Small reporting company	S☒
Emerging growth Company	S☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. S☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes £☐ No S☒

As of August ~~6, 2020,~~2, 2021, the registrant had ~~39,906,066~~45,452,450 shares of common stock $0.0001 par value per share, outstanding.

Table of Contents

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

•the timing, progress and results of preclinical studies and clinical trials for our current product candidates and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;

•the timing, scope or likelihood of regulatory filings and approvals, including timing of Investigational New Drug application and Biological Licensing Application filings for, and final U.S. Food and Drug Administration approval of, our current product candidates and any other future product candidates;

•the timing, scope or likelihood of foreign regulatory filings and approvals;

•our ability to use our understanding of the tumor microenvironment to identify product candidates and to match immunotherapies to select patient subsets;

•our ability to develop and advance our current product candidates and programs into, and successfully complete, clinical studies;

•our ability to develop combination therapies, whether on our own or in collaboration with third parties;

•the impact of COVID-19 on our business operations and that of our third-party manufacturers and suppliers;

•our manufacturing, commercialization and marketing capabilities and strategy;

•the pricing and reimbursement of our current product candidates and other product candidates we may develop, if approved;

•the rate and degree of market acceptance and clinical utility of our current product candidates and other product candidates we may develop;

•the potential benefits of and our ability to maintain our ~~collaboration~~collaborations with Novartis and GSK, and establish or maintain future collaborations or strategic relationships or obtain additional funding;

•our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;

•our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering our current product candidates and other product candidates we may develop, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;

•our competitive position, and developments and projections relating to our competitors and our industry;

•our expectations related to the use of our existing cash, cash equivalents and marketable securities;

•our ability to raise capital to fund operations;

•our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and

•the impact of laws and regulations.

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

Table of Contents


		Page
PART I.	FINANCIAL INFORMATION	3
Item 1.	Financial Statements (unaudited)	3
	Condensed Consolidated Balance Sheets ~~as of~~ ~~June 30, 2020 and December 31, 2019~~	3
	Condensed Consolidated Statements of Operations and Comprehensive ~~Income (Loss) for the Three~~ ~~and Six~~ ~~Months Ended~~ ~~June 30, 2020 and 2019~~Loss	4
	Condensed Consolidated Statements of Stockholders’ Equity ~~for the Three~~ ~~and Six~~ ~~Months Ended~~ ~~June~~ 30 ~~, 2020 and 2019~~	5
	Condensed Consolidated Statements of Cash Flows ~~for the~~ ~~Six~~ ~~Months Ended~~ ~~June 30, 2020 and 2019~~	6
	Notes to Condensed Consolidated Financial Statements (unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2322
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3334
Item 4.	Controls and Procedures	34
PART II.	OTHER INFORMATION	35
Item 1.	Legal Proceedings	35
Item 1A.	Risk Factors	35
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35
Item 3.	Defaults Upon Senior Securities	35
Item 4.	Mine Safety Disclosures	35
Item 5.	Other Information	35
Item 6.	Exhibits	3637
Signatures			3738

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

SURFACE ONCOLOGY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(in thousands, except share and per share data)


		June 30, 2020		December 31, 2019			June 30, 2021		December 31, 2020
Assets	Assets					Assets
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	93,125	$	46,755	Cash and cash equivalents	$	83,335	$	175,141
Marketable securities	Marketable securities	19,414		58,406		Marketable securities	80,945		0
Prepaid expenses and other current assets	Prepaid expenses and other current assets	5,041		2,765		Prepaid expenses and other current assets	6,493		5,368
Total current assets	Total current assets	117,580		107,926		Total current assets	170,773		180,509
Property and equipment, net	Property and equipment, net	6,456		7,286		Property and equipment, net	5,862		6,664
Operating lease right-of-use asset	Operating lease right-of-use asset	28,831		14,858		Operating lease right-of-use asset	26,904		27,911
Restricted cash	Restricted cash	1,595		1,595		Restricted cash	1,595		1,595
Other assets	Other assets	64		28		Other assets	385		459
Total assets	Total assets	$	154,526	$	131,693	Total assets	$	205,519	$	217,138
Liabilities and Stockholders’ Equity	Liabilities and Stockholders’ Equity					Liabilities and Stockholders’ Equity
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable	Accounts payable	$	530	$	3,384	Accounts payable	$	1,187	$	1,674
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	5,250		8,012		Accrued expenses and other current liabilities	8,744		10,448
Deferred revenue - related party		—		4,916
Convertible note payable						Convertible note payable	3,271		0
Operating lease liability	Operating lease liability	4,797		2,962		Operating lease liability	5,494		5,529
Total current liabilities	Total current liabilities	10,577		19,274		Total current liabilities	18,696		17,651
Deferred revenue - related party, non-current		—		33,676
Operating lease liability, non-current	Operating lease liability, non-current	29,692		16,968		Operating lease liability, non-current	27,930		28,981
Convertible note payable, non-current	Convertible note payable, non-current	15,486		5,109		Convertible note payable, non-current	10,804		14,759
Other liabilities		1,100		—
Total liabilities	Total liabilities	56,855		75,027		Total liabilities	57,430		61,391
Commitments and contingencies (Note 12)	Commitments and contingencies (Note 12)					Commitments and contingencies (Note 12)	0		0
Stockholders’ equity:	Stockholders’ equity:					Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at June 30, 2020 and December 31, 2019; 0 shares issued and outstanding at June 30, 2020 and December 31, 2019		—		—
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2020 and December 31, 2019, respectively; 39,257,213 and 27,893,337 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively		4		3
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at June 30, 2021 and December 31, 2020; 0 shares issued and outstanding at June 30, 2021 and December 31, 2020						Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at June 30, 2021 and December 31, 2020; 0 shares issued and outstanding at June 30, 2021 and December 31, 2020	0		0
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2021 and December 31, 2020, respectively; 44,335,609 and 40,707,047 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively						Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2021 and December 31, 2020, respectively; 44,335,609 and 40,707,047 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	5		4
Additional paid-in capital	Additional paid-in capital	211,445		178,155		Additional paid-in capital	244,893		218,001
Accumulated other comprehensive income		54		103
Accumulated other comprehensive loss						Accumulated other comprehensive loss	(9)		0
Accumulated deficit	Accumulated deficit	(113,832)		(121,595)		Accumulated deficit	(96,800)		(62,258)
Total stockholders’ equity	Total stockholders’ equity	97,671		56,666		Total stockholders’ equity	148,089		155,747
Total liabilities and stockholders’ equity	Total liabilities and stockholders’ equity	$	154,526	$	131,693	Total liabilities and stockholders’ equity	$	205,519	$	217,138

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SURFACE ONCOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

(in thousands, except share and per share data)


		Three months ended June 30,						Six months ended June 30,							Three months ended June 30,				Six months ended June 30,
		2020		2019		2020		2019			2021		2020		2021		2020
Collaboration revenue - related party	Collaboration revenue - related party	$	—	$	143	$	38,592	$	14,577	Collaboration revenue - related party	$	0	$	0	$	0	$	38,592
License related revenue										License related revenue	515		0		2,141		0
Total revenue										Total revenue	$	515	$	0	$	2,141	$	38,592
Operating expenses:	Operating expenses:									Operating expenses:
Research and development	Research and development	9,548		13,236		20,836		27,545		Research and development	12,669		9,548		23,213		20,836
General and administrative	General and administrative	4,995		5,417		9,782		10,510		General and administrative	6,434		4,995		12,076		9,782
Total operating expenses	Total operating expenses	14,543		18,653		30,618		38,055		Total operating expenses	19,103		14,543		35,289		30,618
Income (loss) from operations	Income (loss) from operations	(14,543)		(18,510)		7,974		(23,478)		Income (loss) from operations	(18,588)		(14,543)		(33,148)		7,974
Interest and other income, net		(264)		752		(211)		1,521
Interest expense										Interest expense	(416)		(427)		(1,440)		(767)
Other income (expense), net										Other income (expense), net	23		163		46		556
Net income (loss)	Net income (loss)	(14,807)		(17,758)		7,763		(21,957)		Net income (loss)	(18,981)		(14,807)		(34,542)		7,763
Net income (loss) per share attributable to common stockholders— basic	Net income (loss) per share attributable to common stockholders— basic	$	(0.44)	$	(0.64)	$	0.25	$	(0.79)	Net income (loss) per share attributable to common stockholders— basic	$	(0.44)	$	(0.44)	$	(0.81)	$	0.25
Weighted average common shares outstanding— basic	Weighted average common shares outstanding— basic	33,418,412		27,845,136		30,697,779		27,835,471		Weighted average common shares outstanding— basic	43,634,346		33,418,412		42,632,421		30,697,779
Net income (loss) per share attributable to common stockholders— diluted	Net income (loss) per share attributable to common stockholders— diluted	$	(0.44)	$	(0.64)	$	0.24	$	(0.79)	Net income (loss) per share attributable to common stockholders— diluted	$	(0.44)	$	(0.44)	$	(0.81)	$	0.24
Weighted average common shares outstanding— diluted	Weighted average common shares outstanding— diluted	33,418,412		27,845,136		33,763,452		27,835,471		Weighted average common shares outstanding— diluted	43,634,346		33,418,412		42,632,421		33,763,452
Comprehensive income (loss):	Comprehensive income (loss):									Comprehensive income (loss):
Net income (loss)	Net income (loss)	$	(14,807)	$	(17,758)	$	7,763	$	(21,957)	Net income (loss)	$	(18,981)	$	(14,807)	$	(34,542)	$	7,763
Other comprehensive income (loss):	Other comprehensive income (loss):									Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax of $0	Unrealized gain (loss) on marketable securities, net of tax of $0	(116)		169		(49)		293		Unrealized gain (loss) on marketable securities, net of tax of $0	(8)		(116)		(9)		(49)
Comprehensive income (loss)	Comprehensive income (loss)	$	(14,923)	$	(17,589)	$	7,714	$	(21,664)	Comprehensive income (loss)	$	(18,989)	$	(14,923)	$	(34,551)	$	7,714

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SURFACE ONCOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (UNAUDITED)

(in thousands, except share amounts)


		Common Stock													Common Stock
		Shares	Amount		Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total Stockholders’ Equity			Shares	Amount		Additional Paid-in Capital		Accumulated Other Comprehensive Loss		Accumulated Deficit		Total Stockholders’ Equity
Balances at December 31, 2019		27,893,337	$	3	$	178,155	$	103	$	(121,595)	$	56,666
Balances at December 31, 2020													Balances at December 31, 2020	40,707,047	$	4	$	218,001	$	0	$	(62,258)	$	155,747
Issuance of common stock upon exercise of stock options	Issuance of common stock upon exercise of stock options	27,832	—		10		—		—		10		Issuance of common stock upon exercise of stock options	55,761	—		148		—		—		148
Issuance of common stock under stock purchase plan	Issuance of common stock under stock purchase plan	49,025	—		83		—		—		83		Issuance of common stock under stock purchase plan	19,377	—		118		—		—		118
Issuance of common stock upon public offering, net of issuance costs	Issuance of common stock upon public offering, net of issuance costs	91,003	—		320		—		—		320		Issuance of common stock upon public offering, net of issuance costs	1,677,118	1		14,715		—		—		14,716
Issuance of common stock upon conversion of convertible note payable													Issuance of common stock upon conversion of convertible note payable	961,538	—		1,500		—		—		1,500
Stock-based compensation expense	Stock-based compensation expense	—	—		1,850		—		—		1,850		Stock-based compensation expense	—	—		2,380		—		—		2,380
Unrealized gain on marketable securities		—	—		—		67		—		67
Net income		—	—		—		—		22,570		22,570
Balances at March 31, 2020		28,061,197	3		180,418		170		(99,025)		81,566
Unrealized loss on marketable securities													Unrealized loss on marketable securities	—	—		—		(1)		—		(1)
Net loss													Net loss	—	—		—		—		(15,561)		(15,561)
Balances at March 31, 2021													Balances at March 31, 2021	43,420,841	$	5	$	236,862	$	(1)	$	(77,819)	$	159,047
Issuance of common stock upon exercise of stock options	Issuance of common stock upon exercise of stock options	68,426	—		262		—		—		262		Issuance of common stock upon exercise of stock options	358,126	—		1,486		—		—		1,486
Issuance of common stock upon public offering, net of issuance costs	Issuance of common stock upon public offering, net of issuance costs	11,127,590	1		28,765		—		—		28,766		Issuance of common stock upon public offering, net of issuance costs	556,642	—		4,266		—		—		4,266
Stock-based compensation expense	Stock-based compensation expense	—	—		2,000		—		—		2,000		Stock-based compensation expense	—	—		2,279		—		—		2,279
Unrealized loss on marketable securities	Unrealized loss on marketable securities	—	—		—		(116)		—		(116)		Unrealized loss on marketable securities	—	—		—		(8)		—		(8)
Net loss	Net loss	—	—		—		—		(14,807)		(14,807)		Net loss	—	—		—		—		(18,981)		(18,981)
Balances at June 30, 2020		39,257,213	$	4	$	211,445	$	54	$	(113,832)	$	97,671
Balances at June 30, 2021													Balances at June 30, 2021	44,335,609	5		244,893		(9)		(96,800)		148,089


		Common Stock													Common Stock
		Shares	Amount		Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total Stockholders’ Equity			Shares	Amount		Additional Paid-in Capital		Accumulated Other Comprehensive Income		Accumulated Deficit		Total Stockholders’ Equity
Balances at December 31, 2018		27,772,600	$	3	$	169,784	$	(119)	$	(66,806)	$	102,862
Balances at December 31, 2019													Balances at December 31, 2019	27,893,337	$	3	$	178,155	$	103	$	(121,595)	$	56,666
Issuance of common stock upon exercise of stock options	Issuance of common stock upon exercise of stock options	58,082	—		211		—		—		211		Issuance of common stock upon exercise of stock options	27,832	—		10		—		—		10
Issuance of common stock under stock purchase plan													Issuance of common stock under stock purchase plan	49,025	—		83		—		—		83
Issuance of common stock upon public offering, net of issuance costs													Issuance of common stock upon public offering, net of issuance costs	91,003	—		320		—		—		320
Stock-based compensation expense	Stock-based compensation expense	—	—		1,395		—		—		1,395		Stock-based compensation expense	—	—		1,850		—		—		1,850
Unrealized gain on marketable securities	Unrealized gain on marketable securities	—	—		—		124		—		124		Unrealized gain on marketable securities	—	—		—		67		—		67
Net income													Net income	—	—		—		—		22,570		22,570
Balances at March 31, 2020													Balances at March 31, 2020	28,061,197	$	3	$	180,418	$	170	$	(99,025)	$	81,566
Issuance of common stock upon exercise of stock options													Issuance of common stock upon exercise of stock options	68,426	—		262		—		—		262
Issuance of common stock upon public offering, net of issuance costs													Issuance of common stock upon public offering, net of issuance costs	11,127,590	1		28,765		—		—		28,766
Stock-based compensation expense													Stock-based compensation expense	—	—		2,000		—		—		2,000
Unrealized loss on marketable securities													Unrealized loss on marketable securities	—	—		—		(116)		—		(116)
Net loss	Net loss	—	—		—		—		(4,199)		(4,199)		Net loss	—	—		—		—		(14,807)		(14,807)
Balances at March 31, 2019		27,830,682	3		171,390		5		(71,005)		100,393
Issuance of common stock upon exercise of stock options		21,069	—		33		—		—		33
Stock-based compensation expense		—	—		1,485		—		—		1,485
Unrealized gain on marketable securities		—	—		—		169		—		169
Net loss		—	—		—		—		(17,758)		(17,758)
Balances at June 30, 2019		27,851,751	$	3	$	172,908	$	174	$	(88,763)	$	84,322
Balances at June 30, 2020													Balances at June 30, 2020	39,257,213	4		211,445		54		(113,832)		97,671

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SURFACE ONCOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(in thousands)


		Six months ended June 30,							Six months ended June 30,
		2020		2019			2021		2020
Cash flows from operating activities:	Cash flows from operating activities:					Cash flows from operating activities:
Net income (loss)	Net income (loss)	$	7,763	$	(21,957)	Net income (loss)	$	(34,542)	$	7,763
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	Adjustments to reconcile net loss to net cash provided by (used in) operating activities:					Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization expense	Depreciation and amortization expense	852		871		Depreciation and amortization expense	802		852
Stock-based compensation expense	Stock-based compensation expense	3,850		2,880		Stock-based compensation expense	4,659		3,850
Non-cash interest expense related to note payable	Non-cash interest expense related to note payable	377		—		Non-cash interest expense related to note payable	816		377
Net amortization of premiums and discounts on marketable securities	Net amortization of premiums and discounts on marketable securities	(57)		(464)		Net amortization of premiums and discounts on marketable securities	357		(57)
Loss on disposal of property and equipment	Loss on disposal of property and equipment	1		—		Loss on disposal of property and equipment	0		1
Non-cash operating lease cost	Non-cash operating lease cost	1,066		578		Non-cash operating lease cost	1,007		1,066
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Prepaid expenses and other current assets	Prepaid expenses and other current assets	(2,276)		2,526		Prepaid expenses and other current assets	(1,125)		(2,276)
Other assets	Other assets	(36)		29		Other assets	74		(36)
Accounts payable	Accounts payable	(2,854)		(897)		Accounts payable	(487)		(2,854)
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	(2,762)		(847)		Accrued expenses and other current liabilities	(1,704)		(2,762)
Operating lease liability	Operating lease liability	(480)		(551)		Operating lease liability	(1,086)		(480)
Other liabilities	Other liabilities	1,100		—		Other liabilities	0		1,100
Deferred revenue - related party	Deferred revenue - related party	(38,592)		(14,577)		Deferred revenue - related party	0		(38,592)
Net cash used in operating activities	Net cash used in operating activities	(32,048)		(32,409)		Net cash used in operating activities	(31,229)		(32,048)
Cash flows from investing activities:	Cash flows from investing activities:					Cash flows from investing activities:
Purchases of property and equipment	Purchases of property and equipment	(23)		(1,137)		Purchases of property and equipment	0		(23)
Purchases of marketable investments		(650)		(93,459)
Purchases of marketable securities						Purchases of marketable securities	(81,311)		(650)
Proceeds from sales or maturities of marketable securities	Proceeds from sales or maturities of marketable securities	39,650		81,600		Proceeds from sales or maturities of marketable securities	0		39,650
Net cash provided by (used in) investing activities	Net cash provided by (used in) investing activities	38,977		(12,996)		Net cash provided by (used in) investing activities	(81,311)		38,977
Cash flows from financing activities:	Cash flows from financing activities:					Cash flows from financing activities:
Proceeds from issuance of convertible note payable	Proceeds from issuance of convertible note payable	10,000		—		Proceeds from issuance of convertible note payable	0		10,000
Proceeds from issuance of common stock upon public offering, net	Proceeds from issuance of common stock upon public offering, net	29,086		—		Proceeds from issuance of common stock upon public offering, net	18,982		29,086
Proceeds from employee stock purchases	Proceeds from employee stock purchases	83		—		Proceeds from employee stock purchases	118		83
Proceeds from exercise of stock options	Proceeds from exercise of stock options	272		244		Proceeds from exercise of stock options	1,634		272
Net cash provided by financing activities	Net cash provided by financing activities	39,441		244		Net cash provided by financing activities	20,734		39,441
Net increase (decrease) in cash and cash equivalents and restricted cash	Net increase (decrease) in cash and cash equivalents and restricted cash	46,370		(45,161)		Net increase (decrease) in cash and cash equivalents and restricted cash	(91,806)		46,370
Cash and cash equivalents and restricted cash at beginning of period	Cash and cash equivalents and restricted cash at beginning of period	48,350		84,110		Cash and cash equivalents and restricted cash at beginning of period	176,736		48,350
Cash and cash equivalents and restricted cash at end of period	Cash and cash equivalents and restricted cash at end of period	$	94,720	$	38,949	Cash and cash equivalents and restricted cash at end of period	$	84,930	$	94,720
Supplemental disclosure of cash flow information:	Supplemental disclosure of cash flow information:					Supplemental disclosure of cash flow information:
Cash paid for interest	Cash paid for interest	$	346	$	—	Cash paid for interest	$	636	$	346
Supplemental disclosure of non-cash investing and financing activities:	Supplemental disclosure of non-cash investing and financing activities:					Supplemental disclosure of non-cash investing and financing activities:
Additional right-of-use asset and related lease liability	Additional right-of-use asset and related lease liability	$	15,003	$	—	Additional right-of-use asset and related lease liability	$	0	$	15,003
Purchases of property and equipment included in accounts payable and accrued expenses		$	—	$	215
Conversion of note payable into shares of common stock						Conversion of note payable into shares of common stock	$	1,500	$	0

The accompanying notes are an integral part of these financial statements.

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

1. Nature of the Business

Surface Oncology, Inc. (the “Company” or “Surface”) is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (“TME”) for the development of next-generation cancer therapies. Surface was incorporated in April 2014 under the laws of the State of Delaware.

The Company is subject to risks common to early-stage companies in the biotechnology industry including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the ability to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

On May ~~1, 2019, the Company entered into a Capital on Demand~~™ Sales Agreement (the “2019 Sales Agreement”) with JonesTrading Institutional Services LLC (“JonesTrading”) to issue and sell shares of the Company’s common stock of up to $30,000 in gross proceeds, from time to time during the term of the 2019 Sales Agreement, through an “at-the-market” equity offering program under which JonesTrading acted as the Company’s agent and/or principal (the “2019 ATM Facility”). The 2019 ATM Facility provided that JonesTrading was entitled to compensation for its services in an amount of up to 3.0% of the gross proceeds of any shares sold under the 2019 ATM Facility. The Company had no obligation to sell any shares under the 2019 ATM Facility and could, at any time, suspend solicitation and offers under the 2019 Sales Agreement. In the three and six months ended June 30, 2020, the Company sold 11,127,590 and 11,218,593 shares of common stock at-the-market under the 2019 Sales Agreement, resulting in net proceeds of approximately $28,766 and $29,086, respectively. Through June 30, 2020, the Company sold 11,229,174 shares of common stock at-the-market under the 2019 Sales Agreement, resulting in net proceeds of $29,110. As of June 30, 2020, the Company has fully utilized and closed the 2019 ATM Facility.

~~On May~~ 22, 2020, the Company entered into a Capital on Demand™ Sales Agreement (the “2020 Sales Agreement”) with JonesTrading Institutional Services LLC (“JonesTrading") to issue and sell shares of the Company’s common stock of up to $50,000 in gross proceeds, from time to time during the term of the 2020 Sales Agreement, through an “at-the-market” equity offering program under which JonesTrading will act as the Company’s agent and/or principal (the “2020 ATM Facility”). The 2020 ATM Facility provides that JonesTrading will be entitled to compensation for its services in an amount of up to 3.0% of the gross proceeds of any shares sold under the 2020 ATM Facility. The Company has no obligation to sell any shares under the 2020 ATM Facility and may, at any time, suspend solicitation and offers under the 2020 Sales Agreement. ~~Through~~In the three and six months ended June 30, ~~2020,~~2021, the Company ~~has~~sold 556,642 and 2,233,760 shares of common stock, respectively, at-the-market under the 2020 Sales Agreement, resulting in net proceeds of approximately $4,266 and $18,982, respectively. The Company did not ~~sold~~sell any shares of common stock at-the-market under the 2020 Sales ~~Agreement.~~Agreement in 2020.

The Company’s financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has primarily funded its operations with proceeds from ~~the~~private and public sales of ~~redeemable convertible preferred stock,~~its securities, proceeds from a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. (“Novartis”), proceeds from a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited (“GSK”) and issuance of a ~~debt facility~~term loan with K2 Health Ventures LLC ~~and proceeds from the Company’s initial public offering of common stock.~~(“K2HV”). The Company has ~~incurred~~a history of incurring losses and negative cash flows from ~~operations since its inception.~~operations. As of June 30, ~~2020,~~2021, the Company had an accumulated deficit of ~~$113,832.~~$96,800.

The Company expects that its operating losses and negative cash flows will continue for the foreseeable future. As of August ~~11, 2020,~~5, 2021, the issuance date of this Quarterly Report on Form 10-Q, the Company expects that its cash, cash equivalents and marketable securities ~~of $112,539,~~ will be sufficient to fund its operating expenses, debt service obligations and capital expenditure requirements for at least the next 12 months. The future viability of the Company beyond that date is dependent on its ability to raise additional capital to finance its operations.

~~Table of Contents~~

~~SURFACE ONCOLOGY, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

~~(Amounts in thousands, except share and per share data)~~

The Company will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.

Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

The ongoing global outbreak of the novel coronavirus disease (“COVID-19”) has resulted in significant governmental measures being implemented to control the spread of the virus and while the Company cannot predict their scope or the severity of the outbreak, these developments and measures could materially and adversely affect the Company's business, the Company's results of operations and financial condition. The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business and ~~have~~has taken steps to minimize its impact on the Company's business. Although COVID-19 has not yet had a material adverse impact on ~~our~~the Company's operations and ~~our~~its clinical and preclinical programs, the extent to which COVID-19 ultimately impacts the Company's business, results of operations or financial condition will depend on future developments which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken to contain the pandemic or mitigate its impact, among others. Furthermore, for the safety of its employees, the Company has reduced the presence of its ~~scientists~~employees in the Company's ~~labs~~corporate office and is ~~relying on~~working with third parties to conduct ~~many of the~~certain experiments and studies for its research programs. Certain of the Company's third-party service providers have also experienced shutdowns or other business disruptions. As a result, the Company's ability to conduct its business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on the Company's business, results of operations and financial condition.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiary, Surface Securities Corporation, a Massachusetts corporation, after elimination of all intercompany accounts and transactions.

The accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 2 to the financial statements included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March ~~10, 2020.~~9, 2021.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including clinical trials, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact and the economic impact. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates.

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of June 30, ~~2020,~~2021, the condensed consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, ~~2020~~2021 and ~~2019,~~2020, the condensed consolidated statements of cash flows for the six months ended June 30, ~~2020~~2021 and ~~2019,~~2020, and the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, ~~2020~~2021 and ~~2019~~2020 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, ~~2020~~2021 and the results of its operations and its cash flows for the six months ended June 30, ~~2020~~2021 and ~~2019.~~2020. The financial data and other information disclosed in these notes related to the three and six months ended June 30, ~~2020~~2021 and ~~2019~~2020 are also unaudited. The results for the three and six months ended June 30, ~~2020~~2021 are not necessarily indicative of results to be expected for the year ending December 31, ~~2020,~~2021, any other interim periods, or any future year period.

~~Recently Adopted Accounting Pronouncements~~

~~In November 2018, the FASB issued~~ ~~ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606~~, or ASU 2018-18. ASU 2018-18 makes targeted improvements to generally accepted accounting principles for collaborative arrangements, including: (i) clarification that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account, (ii) adding unit-of-account guidance in Topic 808 to align with the guidance in ASC 606, and (iii) a requirement that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under ASC 606 is precluded if the collaborative arrangement participant is not a customer. This guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. This standard became effective for the Company on January 1, 2020 and the adoption of ASU 2018-18 did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

~~In August 2018, the FASB issued ASU 2018-13,~~ ~~Fair Value Measurement (Topic 820): Disclosure Framework – Changes to theDisclosure Requirements for Fair Value Measurement, (“ASU 2018-13”).~~ The new standard provides for changes to the disclosure requirements for recurring and nonrecurring fair value measurements under Topic 820. Provisions of ASU 2018-13 including changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty are required to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments in ASU 2018-13 should be applied retrospectively to all periods presented upon their effective date. ASU 2018-13 is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019, with early adoption permitted. This standard became effective for the Company on January 1, 2020 and did not have a material impact on the Company’s disclosures.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ~~(‘‘~~("ASU ~~2016-13’’~~2016-13"), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes may result in earlier recognition of credit losses. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which narrowed the scope and changed the effective date for non-public entities for ASU 2016-13. The FASB subsequently issued supplemental guidance within ASU No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief ~~(‘‘~~("ASU ~~2019-05’’~~2019-05"). ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For public entities that are Securities and Exchange Commission filers, excluding entities eligible to be smaller reporting companies, ASU 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, ASU 2016-13 is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. This standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that this standard may have on its condensed consolidated financial statements and related disclosures.

~~Table of Contents~~

~~SURFACE ONCOLOGY, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

~~(Amounts in thousands, except share and per share data)~~

Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

3. Marketable Securities

As of June 30, ~~2020,~~2021, the fair value of available-for-sale marketable debt securities by type of security was as follows:


		June 30, 2020															June 30, 2021
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value			Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Marketable debt securities:	Marketable debt securities:									Marketable debt securities:
U.S. Treasury notes	U.S. Treasury notes	$	16,347	$	40	$	—	$	16,387	U.S. Treasury notes	$	65,070	$	7	(14)		$	65,063
U.S. Government agency bonds		3,013		14		—		3,027
U.S. government agency bonds										U.S. government agency bonds	15,884		1		(3)		15,882
		$	19,360	$	54	$	—	$	19,414		$	80,954	$	8	$	(17)	$	80,945

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

The amortized cost and fair value of the Company’s available-for-sale debt securities by contractual maturity are summarized as follows:

June 30, 2020
Amortized
Cost Fair
Value
Maturing in one year or less $ 19,360 $ 19,414
$ 19,360 $ 19,414


	June 30, 2021
	Amortized Cost		Fair Value
Maturing in one year or less	$	43,622	$	43,629
Maturing after one year	37,332		37,316
	$	80,954	$	80,945

As of December 31, ~~2019, the fair value of~~2020, there were 0 available-for-sale marketable debt ~~securities by type of security was as follows:~~

December 31, 2019
Amortized
Cost Gross
Unrealized
Gains Gross
Unrealized
Losses Fair
Value
Marketable debt securities:
U.S. Treasury notes $ 42,795 $ 73 $ — $ 42,868
U.S. Government agency bonds 15,508 31 (1) $ 15,538
$ 58,303 $ 104 $ (1) $ 58,406

~~The amortized cost and fair value of the Company’s available-for-sale securities by contractual maturity are summarized as follows:~~

December 31, 2019
Amortized
Cost Fair
Value
Maturing in one year or less $ 58,303 $ 58,406
$ 58,303 $ 58,406
securities.

The Company determined that there was no material change in the credit risk of these investments. As a result, the Company determined it did 0t hold any investments with an other-than-temporary decline in fair value as of June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

~~Table of Contents~~

~~SURFACE ONCOLOGY, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

~~(Amounts in thousands, except share and per share data)~~

4. Fair Value of Financial Assets

The following tables present information about the Company’s financial assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:


		Fair Value Measurements as of June 30, 2020 using:															Fair Value Measurements as of June 30, 2021 using:
		Level 1		Level 2		Level 3		Total			Level 1		Level 2		Level 3		Total
Cash equivalents:	Cash equivalents:									Cash equivalents:
Money market funds	Money market funds	$	65,719	$	—	$	—	$	65,719	Money market funds	$	61,353	$	0	$	0	$	61,353
Cash										Cash	295		0		0		295
Marketable securities:	Marketable securities:									Marketable securities:
U.S. Treasury notes	U.S. Treasury notes	—		16,387		—		16,387		U.S. Treasury notes	0		65,063		0		65,063
U.S. Government agency bonds		—		3,027		—		3,027
U.S. government agency bonds										U.S. government agency bonds	0		15,882		0		15,882
		$	65,719	$	19,414	$	—	$	85,133		$	61,648	$	80,945	$	0	$	142,593

Fair Value Measurements as of December 31, 2019 using:
Level 1 Level 2 Level 3 Total
Cash equivalents:
Money market funds $ 30,490 $ — $ — $ 30,490
U.S. Government agency bonds — 2,500 — 2,500
Marketable securities:
U.S. Treasury notes — 42,868 — $ 42,868
U.S. Government agency bonds — 15,538 — 15,538
$ 30,490 $ 60,906 $ — $ 91,396


	Fair Value Measurements as of December 31, 2020 using:
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	139,266	$	0	$	0	$	139,266
	$	139,266	$	0	$	0	$	139,266

As of June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, the Company’s cash equivalents were invested in money market funds, U.S Treasury notes and U.S. government agency bonds and were valued based on Level 1 and Level 2 inputs. During the six months ended June 30, ~~2020~~2021 and ~~2019,~~2020, there were 0no transfers between Level 1, Level 2 and Level 3.

1110

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

5. Collaboration and License Agreements

~~Collaboration~~Novartis Agreement ~~with Novartis~~

In January 2016, the Company entered into a collaboration agreement with Novartis (the ~~“Collaboration~~“Novartis Agreement”), which was subsequently amended in May 2016, July 2017, September 2017, and October ~~2018 (the “October 2018 Amendment”).~~2018. Pursuant to the ~~Collaboration~~Novartis Agreement, the Company granted Novartis a worldwide exclusive license to research, develop, manufacture and commercialize antibodies that target cluster of differentiation 73 (“CD73”). In addition, the Company initially granted Novartis the right to purchase exclusive option rights (each an “Option”) for up to ~~four~~4 specified targets (each an “Option Target”) including certain development, manufacturing, and commercialization rights. Novartis initially had the right to exercise up to ~~three~~3 purchased Options. Under the ~~Collaboration~~Novartis Agreement, therefore, Novartis had the ability to exclusively license the development and manufacturing rights for up to ~~four~~4 targets (inclusive of CD73). In January 2020, Novartis did not purchase and exercise its single remaining Option under the ~~Collaboration~~Novartis Agreement and, as a result, the option purchase period expired. Therefore, there are no Options remaining eligible for purchase, and potential exercise, and the Company’s performance obligations under the ~~Collaboration~~Novartis Agreement have ended.

Novartis is a related party because it is a greater than 5% stockholder of the Company. In January 2016, the Company entered into the Collaboration Agreement and sold 2,000,000 shares of its Series A-1 redeemable convertible preferred stock (the “Series A-1 Preferred Stock”) to Novartis, which were subsequently converted to common stock. In addition, concurrent with the Company’s initial public offering of common stock, the Company issued Novartis 766,666 shares of its common stock at $15.00 per share for proceeds of $11,500 in a private placement.

~~During the three and six months ended June 30, 2020 and 2019, the Company made 0 cash payments to Novartis related to the Collaboration Agreement.~~

~~Development and Commercialization of CD73 Products~~

Novartis has the sole right to develop and commercialize CD73 antibody candidates and corresponding licensed products worldwide pursuant to a development plan and a commercialization plan, respectively. Novartis is obligated to use commercially reasonable efforts to develop the CD73 antibody candidates and corresponding licensed products, obtain regulatory approval of such products, including within certain defined markets, and commercialize such products following regulatory approval. Novartis is responsible for all costs and expenses of such development and commercialization and is obligated to provide the Company with updates on its development and commercialization activities through a joint steering committee.

~~Exclusivity~~

Neither the Company nor Novartis may, alone or with any affiliate or third party, develop or commercialize any antibody that specifically binds to CD73. The October 2018 Amendment clarified that Novartis is permitted to research, develop, manufacture or commercialize any diagnostic product that specifically binds to CD73, subject to Novartis’ compliance with its rights and obligations under the Collaboration Agreement, and provided that where such diagnostic product is an Adimab diagnostic product, Novartis may research, develop, manufacture or commercialize such Adimab diagnostic product solely for the purpose of research, development or commercialization of a therapeutic or prophylactic licensed product that specifically binds to the same licensed target.

~~Financial Terms~~

Upon entering into the Collaboration Agreement in January 2016, Novartis made an upfront payment to the Company of $70,000. The Company is also eligible to receive payments upon the achievement of specified development and sales milestones as well as tiered royalties on annual net sales by Novartis ranging from high single-digit to mid-teens percentages, upon successful commercialization of NZV930 (formerly SRF373). Under the ~~Collaboration~~Novartis Agreement, the Company is currently entitled to potential development milestones of ~~$525,000,~~$325,000 and sales milestones of $200,000, as well as tiered royalties on annual net sales by Novartis ranging from high single-digit to mid-teens percentages upon the successful commercialization of ~~NZV930.~~

~~Table of Contents~~

~~SURFACE ONCOLOGY, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

~~(Amounts in thousands, except share and per share data)~~

NZV930 (formerly SRF373).

Termination

Unless terminated earlier, the ~~Collaboration~~Novartis Agreement will continue in effect until neither the Company nor Novartis is researching, developing, manufacturing or commercializing NZV930. Novartis may terminate the ~~Collaboration~~Novartis Agreement for any reason upon prior notice to the Company within a specified time period. Either party may terminate the ~~Collaboration~~Novartis Agreement in full if an undisputed material breach is not cured within a certain period of time or upon notice of insolvency of the other party. To the extent Novartis terminates for convenience, or the Company terminates for Novartis’ material breach, Novartis will grant the Company, on mutually agreeable financial terms, an exclusive, worldwide, irrevocable, perpetual and royalty-bearing license with respect to intellectual property controlled by Novartis that is reasonably necessary to research, develop, manufacture or commercialize NZV930.

Revenue Recognition – Collaboration Revenue – Related Party

In determining the appropriate amount of revenue to be recognized under ASC 606, the Company performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

Under ASC 606, the Company recognized revenue using the cost-to-cost method, which it believes best depicts the transfer of control to the customer. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue will be recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. Under ASC 606, the estimated transaction price will include variable consideration. The Company does not include variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will occur when any uncertainty associated with the variable consideration is resolved. The estimate of the Company’s measure of progress and estimate of variable consideration to be included in the transaction price will be updated at each reporting date as a change in estimate. The amount related to the unsatisfied portion will be recognized as that portion is satisfied over time.

Under ASC 606 the Company ~~accounts~~accounted for (i) the license it conveyed with respect to CD73; and (ii) its obligations to perform research on CD73 and other specified targets as a single performance obligation under the ~~Collaboration~~Novartis Agreement. Novartis’ right to purchase exclusive options to obtain certain development, manufacturing and commercialization rights ~~are~~would have been accounted for separately as they dodid not represent material rights, based on the criteria of ASC 606. Upon the exercise of any purchased option by Novartis, the contract promises associated with an Option Target would ~~use~~have used a separate cost-to-cost model for purposes of revenue recognition under ASC 606.

~~In February 2019, Novartis notified the Company~~

Table of ~~its decision not to purchase the Option related to IL-27. Future costs associated with this target were removed from the estimated total costs~~Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in ~~the cost-to-cost model.~~thousands, except share and per share data)

In January 2020, Novartis did not purchase and exercise its single remaining Option under the ~~Collaboration~~Novartis Agreement and, as a result, the option purchase period expired. Future costs associated with this target were removed from the estimated total costs in the cost-to-cost model. This resulted in the Company recognizing the remaining deferred revenue of $38,592 to collaboration revenue - related party in January 2020.

For the three and six months ended June 30, ~~2020~~2021 and ~~2019,~~2020, the Company recognized the following totals of collaboration revenue – related party:

Three months ended June 30, Six months ended June 30,
2020 2019 2020 2019
Collaboration revenue - related party $ — $ 143 $ 38,592 $ 14,577


	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
Collaboration revenue - related party	$	0	$	0	$	0	$	38,592

GSK Agreement

In December 2020, the Company entered into a license agreement with GSK (the "GSK Agreement"). Pursuant to the GSK Agreement, the Company granted GSK a worldwide, exclusive, sublicensable license to develop, manufacture and commercialize antibodies that target the antibody SRF813, targeting CD112R, also known as PVRIG (the “Licensed Antibodies”). GSK will be responsible for the development, manufacturing and commercialization of the Licensed Antibodies and a joint development committee has been formed to facilitate information sharing between the Company and GSK. Under the terms of the GSK Agreement, GSK is obligated to use commercially reasonable efforts to develop and commercialize the Licensed Antibodies.

Development, Manufacturing and Commercialization of Licensed Antibodies

GSK has the sole right to develop, manufacture and commercialize the Licensed Antibodies and corresponding licensed products worldwide. GSK is obligated to use commercially reasonable efforts to develop the Licensed Antibodies and corresponding licensed products. GSK is responsible for all costs and expenses of such development, manufacturing and commercialization and is obligated to provide the Company with updates on its development, manufacturing and commercialization activities through the joint development committee.

Exclusivity

During the term of the GSK Agreement, neither the Company, nor any affiliates, will research, develop, manufacture, or commercialize any alternative product.

Financial Terms

Under the terms of the GSK Agreement, GSK made a one-time upfront payment of $85,000 and is required to make additional payments to the Company for supply services and transition services, estimated to be $4,499 and $950, respectively. The Company is eligible to receive up to $90,000 in clinical and $155,000 in regulatory milestones. In addition, the Company may receive up to $485,000 in sales milestone payments. The Company is also eligible to receive royalties on global net sales of any approved products based on the licensed antibodies, ranging in percentages from high single digits to mid-teens. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments under the GSK Agreement.

Termination

Unless terminated earlier, the GSK Agreement expires on a licensed product-by-licensed product and country-by-country basis on the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim or regulatory exclusivity covering such licensed product in such country. Either party may terminate the GSK Agreement for an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. GSK may terminate the GSK Agreement for its convenience. The Company may terminate the GSK Agreement if GSK institutes certain actions related to the licensed patents or if GSK ceases development activities, other than for certain specified technical or safety reasons. In the event of termination, the Company would regain worldwide rights to the terminated program.

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

Revenue Recognition –License Related Revenue

In determining the appropriate amount of revenue to be recognized under ASC 606, the Company performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company assessed the GSK Agreement in accordance with ASC 606 and concluded that GSK is a customer. The Company identified the following promises under the contract: (i) a worldwide, exclusive, sublicensable license to develop, manufacture and commercialize the Licensed Antibodies; (ii) supplying Licensed Antibodies until an Investigational New Drug application is accepted by a regulatory authority (iii) transition services until an Investigational New Drug application is accepted by a regulatory authority; and (iv) participation on the joint development and joint patent committees. The Company assessed the above promises and determined that the worldwide, exclusive, sublicensable license to develop, manufacture and commercialize the Licensed Antibodies is considered functional intellectual property and distinct from other promises under the contract. This functional license is distinct in the context of the GSK Agreement as GSK can benefit from the license on its own or together with other readily available resources. In addition, the supply and transition services are not complex or specialized, could be performed by another qualified third party, are not expected to significantly modify or customize the license to SRF813, and are expected to be performed only for a short period of time. The Company determined that the impact of participation on the joint development and joint patent committees was insignificant and had an immaterial impact on the accounting model. Based on these assessments, the Company identified 3 distinct performance obligations at the outset of the GSK Agreement.

The Company determined the transaction price under ASC 606 at the inception of the GSK Agreement to be $90,449, consisting of the upfront payment of $85,000 plus $4,499 for supply of the Licensed Antibodies and $950 for the transition services. The Company evaluated how much variable consideration related to clinical and regulatory milestones to include in the transaction price using the most likely amount approach and concluded that no amount should be included in the transaction price due to the high degree of uncertainty and risk associated with these potential payments. The Company also determined that royalties and sales milestones relate solely to the licenses of intellectual property and are therefore excluded from the transaction price under the sales- or usage-based royalty exception of ASC 606. Revenue related to these royalties and sales milestones will only be recognized when the associated sales occur, and relevant thresholds are met.

As noted above, the Company identified 3 performance obligations in the GSK Agreement: (i) the delivery of the worldwide, exclusive, sublicensable license to develop, manufacture and commercialize the Licensed Antibodies; (ii) supply of Licensed Antibodies until an Investigational New Drug application is accepted by a regulatory authority; and (iii) transition services until an Investigational New Drug application is accepted by a regulatory authority. The selling price of each performance obligation in the GSK Agreement was determined based on the Company’s standalone selling price, with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company recognizes revenue for the license performance obligation at a point in time, that is upon transfer of the license to GSK. As control of the license was transferred on the effective date of December 16, 2020 and GSK could begin to use and benefit from the license, the Company recognized $85,000 of license related revenue during the year ended December 31, 2020 under the GSK Agreement. The Company will recognize $4,499 and $950 allocated to the supply services and transition services over time. The Company transfers control of these services over time and GSK receives and consumes the benefit over time as the Company performs the services. During the three and six months ended June 30, 2021, the Company recognized $299 and $661 of license related revenue, respectively, related to the transition services and recognized $216 and $1,480 of license related revenue, respectively, related to the supply services, which represents the costs incurred for the manufacturing and transition services that were performed.

The aggregate amount of the transaction price allocated to the performance obligations that is partially unsatisfied was $738. The Company expects to recognize the remaining revenue associated with the GSK Agreement in the year ending December 31, 2021. As of June 30, 2021, the Company did not have a contract liability associated with the GSK Agreement. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved, or other changes in circumstances occur, adjust its estimate of the transaction price if necessary.

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

~~The following table presents changes in~~For the ~~Company’s contract liabilities during the~~three and six months ended June 30, ~~2020:~~

December 31, 2019 Additions Deductions June 30, 2020
Contract liabilities ⁽¹⁾

Total deferred revenue - related party $ 38,592 $ — $ (38,592) $ —

~~(1)~~2021 and 2020Additions to contract liabilities relate to consideration from Novartis during the reporting period. Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period.

~~During the six months ended June 30, 2020,~~, the Company recognized ~~$38,592~~ the following totals of ~~revenue~~license related to the amounts included in contract liability balance at the beginning of the period. During the three months ended June 30, 2020, the Company did not recognize any revenue included in the contract liability balance at the beginning of the period.revenue: As ~~there are no Options remaining eligible for purchase and exercise, the Company’s performance obligations under the Collaboration Agreement have ended.~~


	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
License related revenue	$	515	$	0	$	2,141	$	0

6. Stockholders’ Equity

Common Stock

As of June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 150,000,000 shares, of ~~0.0001~~$0.0001 par value common stock.

Each share of common stock entitles the holder to 1 vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of any outstanding preferred stock. NaN dividends have been declared or paid by the Company through June 30, ~~2020.~~2021.

As of June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, the Company had reserved ~~22,896,773~~21,135,780 and ~~17,351,095~~22,728,991 shares, respectively, of common stock for the exercise of outstanding stock options, ~~common stock for~~ the vesting of restricted stock units, shares to be issued under the ~~2019~~2020 ATM Facility, shares to be issued ~~under~~upon the ~~2020 ATM Facility~~conversion of the Loan Agreement (as defined below), and the number of shares remaining available for future grant under the Company’s 2018 Stock Option and Incentive Plan and 2018 Employee Stock Purchase Plan.

InOn May 1, 2019, the Company entered into a Capital on Demand™ Sales Agreement ("the 2019 Sales ~~Agreement~~Agreement") with JonesTrading to issue and sell up to $30,000 in shares of the Company’s common stock from time to time. In the three and six months ended June 30, 2020, the Company sold 11,127,590 and 11,218,593 shares of common stock at-the-market under the 2019 Sales Agreement, resulting in net proceeds of approximately $28,766 and $29,086, respectively. ~~Through~~As of June 30, 2020, the Company ~~has~~ sold 11,229,174 shares of common stock at-the-market under the 2019 Sales Agreement for net proceeds of ~~$29,110. As of June 30, 2020, the Company has~~$29,110, and had fully utilized and closed the 2019 ATM Facility.

In May 2020, the Company entered into the 2020 Sales Agreement with JonesTrading to issue and sell up to $50,000 in shares of the Company's common stock, from time to time. ~~Through~~In the three and six months ended June 30, ~~2020,~~2021, the Company ~~has not~~ sold 556,642 and 2,233,760 shares of common stock at-the-market under the 2020 Sales Agreement, resulting in net proceeds of approximately $4,266 and $18,982, respectively. The Company did 0t sell any shares of common stock at-the-market under the 2020 Sales ~~Agreement.~~Agreement in 2020.

~~Table of Contents~~

~~SURFACE ONCOLOGY, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

~~(Amounts in thousands, except share and per share data)~~

7. Stock-Based Awards

2014 Stock Incentive Plan

The Company’s 2014 Stock Incentive Plan (the “2014 Plan”) provides for the Company to grant incentive stock options or nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, directors and consultants of the Company. The 2014 Plan is administered by the board of directors, or at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of the stock options may not be less than 100% of the fair market value of a share of the Company’s common stock on the date of grant and the term of the stock options may not be greater than ten years.

As of December 31, 2018, all remaining shares available under the 2014 Plan were transferred to the Company’s 2018 Stock Option and Incentive Plan (the “2018 Plan”).

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

2018 Stock Option and Incentive Plan

In April 2018, the Company’s 2018 Plan was approved by its stockholders and became effective. The 2018 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, non-employee directors and other key persons (including consultants). The number of shares initially reserved for issuance under the 2018 Plan was 1,545,454, plus the shares of common stock remaining available for issuance under the 2014 Plan, which shall be cumulatively increased each January 1 by 4% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company’s board of directors or compensation committee of the board of directors. The shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Plan and the 2014 Plan will be added back to the shares of common stock available for issuance under the 2018 Plan.

As of June 30, ~~2020, 603,143~~2021, 741,294 shares were available for future issuance under the 2018 Plan.

Stock options granted under the 2014 Plan and 2018 Plan to employees generally vest over four years and expire after ten years.

Stock Options

The following table summarizes the Company’s stock option activity since ~~January 1,~~December 31, 2020:

Number of
Shares Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term Aggregate
Intrinsic
Value
(in years)
Outstanding as of December 31, 2019 5,418,113 $ 6.11 7.69 $ 690
Granted 1,254,000 3.23
Exercised (96,258) 2.82
Forfeited (389,991) 6.61
Outstanding as of June 30, 2020 6,185,864 $ 5.54 7.74 $ 13,419
Options exercisable at June 30, 2020 3,403,399 $ 5.63 6.99 $ 7,397
Vested and expected to vest at June 30, 2020 6,185,864 $ 5.54 7.74 $ 13,419


	Number of Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
				(in years)
Outstanding as of December 31, 2020	6,011,126	$	5.55	7.28	$	24,912
Granted	1,669,505	9.34
Exercised	(413,887)	3.95
Forfeited	(72,074)	5.16
Outstanding as of June 30, 2021	7,194,670	$	6.53	7.42	$	15,289
Options exercisable at June 30, 2021	4,181,153	$	6.01	6.37	$	10,728
Vested and expected to vest at June 30, 2021	7,194,670	$	6.53	7.42	$	15,289

The weighted average grant-date fair value per share of stock options granted during the six months ended June 30, ~~2020~~2021 and year ended December 31, ~~2019~~2020 was ~~$2.04~~$6.58 and ~~$2.71,~~$2.11, respectively.

~~Table of Contents~~

~~SURFACE ONCOLOGY, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

~~(Amounts in thousands, except share and per share data)~~

As of June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, there were outstanding stock options held by non-employees for the purchase of ~~267,372~~240,570 and ~~272,343~~253,971 shares of common stock, respectively, with service-based vesting conditions.

2018 Employee Stock Purchase Plan

In April 2018, the Company’s 2018 Employee Stock Purchase Plan (the “ESPP”) was approved by its stockholders and became effective. A total of 256,818 shares of common stock were initially reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the ESPP automatically increased on January 1, 2019, and shall increase each January 1 thereafter through January 1, 2028, by the lesser of (i) 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31 and (ii) such lesser number of shares as determined by the administrator of the Company’s ESPP. As of June 30, ~~2020,~~2021, a total of ~~764,452~~1,111,998 shares of common stock were reserved for issuance under this plan.

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

For the six months ended June 30, 2021 and 2020, the Company issued 19,377 and 49,025 shares of common stock under the ~~ESPP. For~~ESPP, respectively. The Company did 0t issue shares of common stock under the ESPP in the three months ended June 30, ~~2020 and three and six months ended June 30, 2019, the Company did 0t issue any shares of common stock under the ESPP.~~2021 or 2020.

Restricted Stock Units

The Company has granted restricted stock units ~~("RSUs"~~(“RSUs”) with service-based vesting conditions. RSUs represent the right to receive shares of common stock upon meeting specified vesting requirements. Unvested shares of restricted common stock may not be sold or transferred by the holder. These restrictions lapse according to the service-based vesting conditions of each award. In ~~February~~ 2020, the Company granted ~~1,060,900~~1,071,400 RSUs that vest in full after eighteen-months as long as the individual remains an employee of the Company at such time.

The table below summarizes the Company’s restricted stock unit activity since December 31, ~~2019:~~2020:


		Number of Shares	Weighted Average Grant-Date Fair Value			Number of Shares	Weighted Average Grant-Date Fair Value
Unvested restricted stock units as of December 31, 2019		—	$	—
Unvested restricted stock units as of December 31, 2020					Unvested restricted stock units as of December 31, 2020	1,043,300	$	3.21
Granted	Granted	1,060,900	3.18		Granted	0	0
Vested	Vested	—	—		Vested	0	0
Forfeited	Forfeited	(3,300)	3.18		Forfeited	(45,900)	3.18
Unvested restricted stock units as of June 30, 2020		1,057,600	$	3.18
Unvested restricted stock units as of June 30, 2021					Unvested restricted stock units as of June 30, 2021	997,400	$	3.21

The expense related to RSUs granted to employees was $612 and $1,155, and $560 and $990 for the three and six months ended June 30, 2021 and 2020, respectively.

At June 30, 2020, there was $2,373 of total unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over the remaining weighted-average vesting period of 1.06 years.

~~Table of Contents~~

~~SURFACE ONCOLOGY, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

~~(Amounts in thousands, except share and per share data)~~

Stock-Based Compensation

The Company recorded stock-based compensation expense related to stock options and restricted stock unit awards in the following expense categories of its condensed consolidated statements of operations and comprehensive ~~income (loss):~~loss:


		Three months ended June 30,						Six months ended June 30,							Six months ended June 30,
		2020		2019		2020		2019			2021		2020
Research and development expenses	Research and development expenses	$	743	$	607	$	1,425	$	1,172	Research and development expenses	$	1,687	$	1,425
General and administrative expenses	General and administrative expenses	1,257		878		2,425		1,708		General and administrative expenses	2,972		2,425
		$	2,000	$	1,485	$	3,850	$	2,880		$	4,659	$	3,850

Included in the stock compensation expense recognized during the three and six months ended June 30, 2021 is $28 and $422 of stock-based compensation, respectively, resulting from modifications to previously issued stock option awards in connection with the transition of the Company's Chief Executive Officer to Chairman of the Board, which is recorded in general and administrative expense. As of June 30, ~~2020,~~2021, the Company had an aggregate of ~~$12,055~~$15,745 of unrecognized stock-based compensation cost, which is expected to be recognized over a weighted average period of ~~1.98~~1.46 years.

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

8. Debt

On November 22, 2019, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with ~~K2 HealthVentures LLC~~K2HV (the “Lender”). The Lender has agreed to make available to the Company term loans in an aggregate principal amount of up to $25,000 under the Loan Agreement. The Company plans to use the proceeds of the term loans to support clinical development as well as for working capital and general corporate purposes. The Loan Agreement provides a term loan commitment of $25,000 in three potential tranches: (i) a $7,500 term loan facility funded on November 22, 2019 (the “First Tranche Term Loan”), (ii) a $10,000 term loan facility funded on June 5, 2020 (the “Second Tranche Term Loan”), and (iii) a $7,500 term loan facility (the “Third Tranche Term Loan”). All 3 of these term loans have a maturity date of December 1, 2023.

Borrowings under all three loan facilities bear interest at a floating per annum rate equal to the greater of (i) 8.65% and (ii) the Prime Rate plus 3.90%. The Company is permitted to make interest-only payments on the First Tranche Term Loan for the first eighteen months following the funding date. The interest-only period can be extended by an additional six months, subject to the funding of the Second Tranche Term Loan; and by an additional six months, subject to the funding of the Third Tranche Term Loan. The term of the combined facility will be 48 months, with repayment in monthly installments commencing at the end of the resulting interest-only period as outlined above through the end of the 48-month term.

The Company is obligated to pay a final fee equal to 4.45% of the aggregate amount of the term loans funded, such payment to occur upon the earliest of (i) the maturity date, (ii) the acceleration of the term loans, and (iii) the prepayment of the term loans. The Company has the option to prepay all, but not less than all, of the outstanding principal balance of the term loans under the Loan Agreement. If the Company prepays all of the term loans prior to the maturity date, it will pay the Lender a prepayment penalty fee based on a percentage of the outstanding principal balance, equal to 5% if the payment occurs on or before 24 months after the initial funding date, 3% if the prepayment occurs more than 24 months after, but on or before 36 months after the initial funding date, or 1% if the prepayment occurs more than 36 months after the initial funding date.

The Lender may, at its option, elect to convert any portion of no more than $4,000 of the then outstanding term loan amount and all accrued and unpaid interest thereon into shares of the Company’s common stock at a conversion price of $1.56 per share. The Company determined that the embedded conversion option is not required to be separated from the term loan. The embedded conversion option meets the derivative accounting scope exception since the embedded conversion option is indexed to the Company’s own common stock and qualifies for classification within stockholders’ equity. The Company ~~did recognize~~recognized a beneficial conversion feature of $2,101, which represents the difference between the commitment date stock price of $2.33 per share and the conversion price of $1.56 per share. The beneficial conversion feature was recorded as a discount on the term loan and is accreted to interest expense using the effective interest method over the term of the loan. The effective interest rate of the term loan as of June 30, 2021 is ~~16.49%~~12.36%.

The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets. The Loan Agreement contains customary representations, warranties and also includes customary events of default, including payment defaults, breaches of covenants, change of control and a material adverse effect clause.

~~Table of Contents~~

~~SURFACE ONCOLOGY, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

~~(Amounts in thousands, except share and per share data)~~

Upon the occurrence of an event of default, a default interest rate of an additional 5.00% per annum may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and exercise all of its rights and remedies as set forth in the Loan Agreement and under applicable law.

In June 2020, the Company drew down the Second Tranche Term Loan and received an additional $10,000 in proceeds. The Company is permitted to make interest-only payments on the First Tranche Term Loan and the Second Tranche Term Loan until January 2022 in accordance with the terms of the Loan Agreement.

In August 2020, the Lender elected to convert $2,000 of the outstanding term loan amount into 1,282,050 shares of the Company's common stock, in accordance with the Loan Agreement. In February 2021, the Lender elected to convert $1,500 of the outstanding term loan amount into 961,538 shares of the Company's common stock, in accordance with the Loan Agreement. The Company ~~recorded~~recognized $563 of interest expense ~~related to~~in the ~~loan facility of $427 and $767 for the three and~~ six months ended June 30, ~~2020, respectively. The fair value~~2021 from accelerating amortization of the ~~loan at~~beneficial conversion feature and debt discount as a result of the conversion in February 2021. As of June 30, ~~2020 approximates its face amount due to~~2021, the ~~floating interest rate.~~

~~Future~~outstanding principal ~~debt payments on the loan payable are as follows:~~

June 30, 2020
2020 $ —
2021 —
2022 8,356
2023 9,144
Total principal payments 17,500
Final fee due at maturity in 2024 779
Total principal payments and final fee 18,279
Unamortized debt discount and final fee 2,793
Note payable $ 15,486
balance was $14,000.

1817

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

The Company recorded interest expense related to the loan facility of $413 and $1,437, and $427 and $767 for the three and six months ended June 30, 2021 and 2020, respectively. The fair value of the loan at June 30, 2021 approximates its face amount due to the floating interest rate.

Future principal debt payments on the loan payable are as follows:


	June 30, 2021
2021	$	0
2022	6,685
2023	7,315
Total principal payments	14,000
Final fee due at maturity in 2024	779
Total principal payments and final fee	14,779
Unamortized debt discount and final fee	(704)
Note payable	$	14,075

9. Net Loss per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:


		Three months ended June 30,						Six months ended June 30,							Three months ended June 30,				Six months ended June 30,
		2020		2019		2020		2019			2021		2020		2021		2020

		Basic net income (loss) per share attributable to common stockholders:
Basic net income (loss) per share attributable to common stockholders:										Basic net income (loss) per share attributable to common stockholders:
Numerator:	Numerator:									Numerator:
Net income (loss)	Net income (loss)	$	(14,807)	$	(17,758)	$	7,763	$	(21,957)	Net income (loss)	$	(18,981)	$	(14,807)	$	(34,542)	$	7,763
Denominator:	Denominator:									Denominator:
Weighted average commons shares outstanding — basic		33,418,412		27,845,136		30,697,779		27,835,471
Weighted average common shares outstanding — basic										Weighted average common shares outstanding — basic	43,634,346		33,418,412		42,632,421		30,697,779
Net income (loss) per share attributable to common stockholders — basic	Net income (loss) per share attributable to common stockholders — basic	$	(0.44)	$	(0.64)	$	0.25	$	(0.79)	Net income (loss) per share attributable to common stockholders — basic	$	(0.44)	$	(0.44)	$	(0.81)	$	0.25

		Diluted net income (loss) per share attributable to common stockholders:
Diluted net income (loss) per share attributable to common stockholders:										Diluted net income (loss) per share attributable to common stockholders:
Numerator:	Numerator:									Numerator:
Net income (loss) attributable to common shareholders - basic	Net income (loss) attributable to common shareholders - basic	$	(14,807)	$	(17,758)	$	7,763	$	(21,957)	Net income (loss) attributable to common shareholders - basic	$	(18,981)	$	(14,807)	$	(34,542)	$	7,763
Interest expense on convertible note payable	Interest expense on convertible note payable	—		—		351		—		Interest expense on convertible note payable	0		0		0		351
Net income (loss) attributable to common shareholders - diluted	Net income (loss) attributable to common shareholders - diluted	$	(14,807)	$	(17,758)	$	8,114	$	(21,957)	Net income (loss) attributable to common shareholders - diluted	$	(18,981)	$	(14,807)	$	(34,542)	$	8,114
Denominator:	Denominator:									Denominator:
Weighted average commons shares outstanding — basic		33,418,412		27,845,136		30,697,779		27,835,471
Weighted average common shares outstanding - basic										Weighted average common shares outstanding - basic	43,634,346		33,418,412		42,632,421		30,697,779
Shares issuable upon conversion of convertible notes, as if converted	Shares issuable upon conversion of convertible notes, as if converted	—		—		2,564,102		—		Shares issuable upon conversion of convertible notes, as if converted	0		0		0		2,564,102
Dilutive effect of restricted stock units	Dilutive effect of restricted stock units	—		—		107,284		—		Dilutive effect of restricted stock units	0		0		0		107,284
Dilutive effect of common stock equivalents	Dilutive effect of common stock equivalents	—		—		394,287		—		Dilutive effect of common stock equivalents	0		0		0		394,287
Weighted average common shares outstanding - diluted	Weighted average common shares outstanding - diluted	33,418,412		27,845,136		33,763,452		27,835,471		Weighted average common shares outstanding - diluted	43,634,346		33,418,412		42,632,421		33,763,452
Net income (loss) per share attributable to common stockholders — diluted		$	(0.44)	$	(0.64)	$	0.24	$	(0.79)
Net income (loss) per share attributable to common stockholders - diluted										Net income (loss) per share attributable to common stockholders - diluted	$	(0.44)	$	(0.44)	$	(0.81)	$	0.24

~~Stock options for the purchase~~

Table of ~~5,599,782 weighted average shares were~~Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

The Company’s potential dilutive securities have been excluded from the computation of diluted net ~~income~~loss per share for the three and six months ended June 30, 2021, as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the ~~six months ended June 30, 2020~~periods indicated above because ~~those options~~including them would have had an anti-dilutive ~~impact due to the assumed proceeds per share using the treasury stock method being greater than the average fair value of the Company’s common shares for those periods.~~ effect:


	June 30,
	2021	2020
Stock options to purchase common stock	7,194,670	5,599,782
Shares to be issued under the 2018 ESPP	1,111,998	0
RSUs issued and expecting to vest	997,400	0
Shares available from conversion of note payable	320,514	0
	9,624,582	5,599,782

10. Income Taxes

The Company did 0t provide for any income taxes for the three and six months ended June 30, ~~2020~~2021 or ~~2019.~~2020.

The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of June 30, ~~2020~~2021 and December 31, ~~2019.~~2020. Management reevaluates the positive and negative evidence at each reporting period.

~~Table of Contents~~

~~SURFACE ONCOLOGY, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

~~(Amounts in thousands, except share and per share data)~~

As of June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, the Company had 0 accrued interest or tax penalties recorded. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. ~~During July 2020, the Company received notice of completion by the Internal Revenue Service ("IRS") for the period ended December 31, 2016. No adjustments were proposed.~~ The Company's tax years are still open under statute from ~~2015~~2017 to present. All years may be examined to the extent the tax credit or net operating loss carryforwards are used in future periods. There are currently no federal or state audits.

11. Leases

The Company leases real estate, primarily its corporate headquarters in Cambridge, Massachusetts. The Company’s leases have remaining terms ranging from less than 1 year to 10 years. Certain leases include options to renew, exercised at the Company’s sole discretion, with renewal terms that can extend the lease five years. The Company evaluated the renewal options in its leases to determine if it was reasonably certain that the renewal option would be exercised, and therefore should be included in the calculation of the operating lease assets and operating lease liabilities. Given the Company’s current business structure, uncertainty of future growth, and the associated impact to real estate, the Company concluded that it is not reasonably certain that the renewal option related to its corporate headquarters would be exercised. However, for leases it determined the renewal option was probable to be exercised, the Company included the renewal period in the calculation of the operating lease right-of-use assets and operating lease liabilities. All of the Company’s leases qualify as operating leases. With the adoption of the new leasing standard, the Company has recorded a right-of-use asset and corresponding lease liability, by calculating the present value of future lease payments, discounted at either 9.5% or 10.5%, the Company’s incremental borrowing rates, over the expected term. The right-of-use asset is reduced by any lease incentives received and the legacy deferred rent balance.

In May 2016, the Company entered into an operating lease agreement for its corporate headquarters in Cambridge, Massachusetts, with a 10-year term that expires in February 2027 (“Initial Space”). Rental payments related to the lease commenced in April 2017. In connection with this lease, the Company was entitled to cash incentives from the landlord to be used for the construction of leasehold improvements within the facility. As of January 1, 2019, the Company was entitled to $4,803 of such incentives, which were recorded as a reduction to the right-of-use asset and included as a straight-line reduction to lease expense over the lease term.

In May 2018, the Company executed an amendment to lease an additional 33,526 square feet at 50 Hampshire Street in Cambridge, Massachusetts, with a 10-year term (“Expansion Space”). This additional space became available for occupancy on January 1, 2020 and rental payments related to the lease commenced in April 2020. In connection with this lease amendment, the Company is entitled to a landlord-provided tenant improvement allowance of up to $1,005 to be applied to the cost of the construction of leasehold improvements. The Company determined that it owns the leasehold improvements and, as such, reflected the $1,005 lease incentive as a reduction of the rental payments used to measure the operating lease liability, and, in turn, the operating lease right of use asset as of the lease commencement date.

~~The components of the Company’s lease expense are as follows:~~

Lease Costs Classification Three months ended June 30, 2020 Three months ended June 30, 2019 Six months ended June 30, 2020 Six months ended June 30, 2019
Operating lease cost R&D Expense $ 511 $ 572 $ 1,051 $ 1,158
G&A Expense 826 237 1,624 461
Variable lease costs⁽¹⁾
R&D Expense 117 169 315 341
G&A Expense 254 70 553 136
Total lease cost $ 1,708 $ 1,048 $ 3,543 $ 2,096
Weighted-average remaining lease term (in months) 115.43 121.60
Weighted-average discount rate 10.5 % 10.4 %

~~(1)~~Variable lease costs include certain additional charges for operating costs, including insurance, maintenance, taxes, utilities, and other costs incurred, which are billed based on both usage and as a percentage of the Company’s share of total square footage. Short term lease costs are immaterial.

~~Table of Contents~~

~~SURFACE ONCOLOGY, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

~~(Amounts in thousands, except share and per share data)~~

~~Cash paid for amounts included in the measurement of the Company’s operating lease liabilities was $1,719 and $3,131 for the three and six months ended June 30, 2020, respectively.~~

~~As of June 30, 2020, the maturities of the Company’s operating lease liabilities were as follows:~~

Year Ending December 31,
2020 $ 1,705
2021 5,529
2022 5,385
2023 5,413
2024 5,533
Thereafter 31,521
Total future lease payments 55,086
Less: Interest (20,597)
Present value of future lease payments (lease liability) $ 34,489

~~Future minimum lease payments for the Company’s operating leases as of December 31, 2019 were as follows:~~

Year Ending December 31,
2020 $ 4,802
2021 5,529
2022 5,385
2023 5,413
2024 5,533
Thereafter 31,827
$ 58,489

Sublease Agreement with EQRx, Inc.

In ~~December 2019,~~the three and six months ended June 30, 2021 and 2020, the Company ~~entered into a~~recognized sublease ~~agreement with EQRx, Inc. to sublease the entire Expansion Space. The term~~income of ~~the sublease agreement commenced in January 2020~~$656 and ends on the last day of the 36th calendar month following commencement, with no option to extend.The annual rent for the subleased premises is greater than the annual rent owed by the Company to the landlord for the leased premises. The sublessee is obligated to pay all real estate taxes$1,313, and ~~costs related to the subleased premises, including cost of operations, maintenance, repair, replacement~~$547 and property management. The Company concluded that the sublease is an operating lease. Consistent with the Company’s policy election for lessor operating leases, each lease component and its associated non-lease components is accounted for as a single lease component.$1,094, respectively.

As of June 30, ~~2020,~~2021, future undiscounted cash inflows under the sublease are as follows:


Year Ending December 31,	Year Ending December 31,			Year Ending December 31,
2020		$	1,264
2021	2021	2,579		2021	$	1,417
2022	2022	2,635		2022	2,884
2023	2023	220		2023	241
		$	6,698		$	4,542

2119

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

12. Commitments and Contingencies

Legal Proceedings

The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to its legal proceedings.

Adimab Development and Option Agreement

During the three and six months ended June 30, 2021, the Company recognized research and development expense related to milestones achieved under the agreement of $1,500. During the three and six months ended June 30, 2020, the Company recognized research and development expense related to milestones achieved under the agreement of $2,000.

13. Related Party Transactions

Novartis Institutes for BioMedical Research, Inc.

Novartis is a related party because it is a greater than 5% stockholder of the Company. In January 2016, the Company entered into the ~~Collaboration~~Novartis Agreement and sold 2,000,000 shares of its Series A-1 Preferred Stock to Novartis for gross proceeds of $13,500. In addition, concurrent with the Company’s initial public offering of common stock, the Company issued Novartis 766,666 shares of its common stock at $15.00 per share, for proceeds of $11,500 in a private placement. ~~During~~The Company did 0t recognize any collaboration revenue - related party under the ~~three and~~Novartis Agreement in the six months ended June 30, ~~2020, the~~2021. The Company recognized $38,592 ofin collaboration revenue - related party in the six months ended June 30, 2020. The Company did 0t recognize any collaboration revenue - related party under the ~~Collaboration Agreement.~~Novartis Agreement in the three months ended June 30, 2021 or 2020. As of June 30, ~~2020~~2021 and ~~2019,~~2020, 0 amounts were due from Novartis.

During the three and six months ended June 30, ~~2020~~2021 and ~~2019,~~2020, the Company made 0 cash payments to Novartis related to the ~~Collaboration~~Novartis Agreement.

~~Research Agreement with~~ Vaccinex, Inc.

On November 30, 2017, the Company entered into ana research agreement (the “Vaccinex Research Agreement”) with Vaccinex, Inc. (“Vaccinex”) ~~whereby~~, pursuant to which Vaccinex ~~will use~~used its technology to assist the Company with identifying and selecting experimental human monoclonal antibodies against targets selected by the Company. On March 23, 2021, the Company exercised its option under the Vaccinex Research Agreement to enter into an exclusive license agreement (the “Vaccinex License Agreement”) to certain antibodies generated under the Vaccinex Research Agreement. The Company’s Chairman of the Board and former Chief Executive Officer is a member of the board of directors of Vaccinex. During the six months ended June 30, 2021, the Company paid Vaccinex $850 relating to the Vaccinex License Agreement. The payment was recognized as research and development expense. Vaccinex is eligible to receive up to an aggregate of $3,500 based on achievement of certain clinical milestones and up to an aggregate of $11,500 based on achievement of certain regulatory milestones per Licensed Product. The Company also owes low single digit royalties on global net sales of any approved Licensed Products.The Company did 0t make any payments to Vaccinex under the License Agreement in the three months ended June 30, 2021 or the three and six months ended June 30, 2020. During the three and six months ended June 30, 2021 and 2020, the Company made 0 payments relating to the ~~agreement. During the three and six months ended June 30, 2019, the Company paid~~ Vaccinex ~~an aggregate of $94 and $177, respectively, relating to the agreement. The payments were recognized as research and development expense.~~Research Agreement. There was 0 amount due by the Company to Vaccinex under either of the Vaccinex Research Agreement or the Vaccinex License Agreement as of June 30, ~~2020 and 2019.~~2021 or 2020.

2220

Table of Contents

SURFACE ONCOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Amounts in thousands, except share and per share data)

14. Subsequent Events

On August 5, 2021, the Company entered into Amendment No. 1 to Capital on DemandTM Sales Agreement (the “Amendment”) with JonesTrading, which amends the 2020 Sales Agreement to allow the issuance and sale of the lesser of (a) the dollar amount of shares of Common Stock registered on the applicable effective Registration Statement (as defined in the Amendment) pursuant to which the offering is being made, (b) the number of authorized but unissued shares of Common Stock, (c) the number or dollar amount of shares of Common Stock permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable) or (d) the number or dollar amount of shares of Common Stock for which the Company has filed a Prospectus Supplement (as defined in the Amendment) (such lesser amount, the “Placement Shares”), from time to time during the term of the 2020 Sales Agreement (as amended, the “2021 ATM Facility”), through an “at-the-market” equity offering program under which JonesTrading will act as the Company’s sales agent. The 2021 ATM Facility provides that JonesTrading will continue to be entitled to compensation for its services in an amount of up to 3.0% of the gross proceeds of any shares sold under the 2021 ATM Facility. The Company has no obligation to sell any shares under the 2021 ATM Facility and may, at any time, suspend solicitation and offers under the 2021 ATM Facility. The issuance and sale, if any, of the Placement Shares by the Company under the 2021 ATM Facility will be made pursuant to a registration statement on Form S-3 and prospectus related thereto, which authorizes an aggregate offering price of up to $80,000 under the 2021 ATM Facility. As of June 30, 2021 and as of the date of the filing of this Quarterly Report on Form 10-Q, the Company had not sold any shares under the 2021 ATM Facility.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and related notes for the year ended December 31, ~~2019~~2020 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission or SEC.

Overview

We are a clinical-stage immuno-oncology company focused on using our specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment, or the TME, for the development of next-generation cancer therapies. While first-generation immuno-oncology therapies, such as checkpoint inhibitors, ~~represent~~represented a remarkable therapeutic advancement, we believe most patients do not achieve durable clinical benefit primarily because these therapies focus on only one element of the complex and interconnected immunosuppressive TME. We believe there is a significant opportunity to more broadly engage both the innate and adaptive arms of the immune system in a multi-faceted, coordinated and patient-specific approach, to meaningfully improve cure rates for patients with a variety of cancers.

We aim to identify key components within the TME to gain a deep understanding of its biology, leverage this understanding to define the optimal therapeutic targets and the patients most likely to benefit, and develop novel antibody therapeutics with differentiated biologic activity. By utilizing our expertise in immunology, oncology, assay development, antibody selection and characterization, and translational research, we are developing and advancing a broad pipeline of TME-focused programs that we believe are the next generation of immuno-oncology therapies. Our programs demonstrate our multi-faceted approach by targeting several critical components of the immunosuppressive TME.

NZV930 (formerly SRF373) and SRF617 are antibodies inhibiting ~~CD73~~cluster of differentiation, or CD, 73 and CD39, respectively, and illustrate how our specialized knowledge of TME biology can be leveraged across programs. CD73 and CD39 are both critical enzymes involved in the production of extracellular adenosine, a key metabolite with strong immunosuppressive properties within the TME. NZV930 and SRF617 each aim to reduce the production of immunosuppressive adenosine, but target different points of the adenosine pathway. In addition ~~inhibition~~to reducing the production of ~~CD39 results in an increase in the pro-inflammatory metabolite~~adenosine, we believe SRF617 will also stimulate anti-tumor immunity because of its ability to maintain levels of extracellular adenosine triphosphate, or ATP, ~~within the TME.~~a proinflammatory molecule. In June 2018, a Phase 1 trial of NZV930 was initiated by our partner, ~~Novartis Institutes for Biomedical Research, Inc., or~~ Novartis. We ~~dosed the first patient in~~initiated a Phase 1/1b dose escalation ~~clinical~~ trial of SRF617 onin March ~~17, 2020.~~2020 and initiated combination cohorts of the ongoing trial in January 2021. SRF617 received Orphan Drug Designation from FDA for the treatment of pancreatic cancer in March 2021. In June 2021, we presented initial clinical data demonstrating SRF617's potential as a combination therapy.

SRF388 is an antibody targeting interleukin 27, or IL-27, an immunosuppressive cytokine, or protein secreted by cells, in the TME that is overexpressed in certain cancers, including hepatocellular, lung and renal cell carcinoma. ~~IL-27 is a cytokine secreted by macrophages and antigen presenting cells that plays an important physiologic role in suppressing the immune system.~~ Due to its immunosuppressive nature, there is a rationale for inhibiting IL-27 to treat cancer, as this approach will influence the activity of multiple types of immune cells that are necessary to recognize and attack a tumor. We ~~dosed the first patient in~~initiated a Phase 1 dose escalation clinical trial of SRF388 onin April ~~23,~~2020, and initiated expansion stages of the ongoing trial in June 2021. SRF388 received Orphan Drug Designation and Fast Track Designation from FDA for the treatment of hepatocellular carcinoma in November 2020. In June 2021, we presented initial clinical data at the American Society of Clinical Oncology Annual Meeting demonstrating monotherapy activity.

SRF813 is an antibody targeting CD112R, also known as PVRIG, an inhibitory protein expressed on natural killer, or NK, and T cells. SRF813 ~~binds a distinct epitope on CD112R and~~ blocks the interaction of CD112R with CD112, its binding partner that is expressed on tumor cells. SRF813 can promote the activation of both NK and T cells, with potential to elicit a strong anti-tumor response and promote immunological memory. In October 2019, we formally declared SRF813 as a development candidate resulting in the initiation of IND-enabling activities. On December 16, 2020, we granted GSK, an exclusive license to worldwide development and commercialization rights of SRF813.

SRF114 is ana highly specific antibody targeting ~~the~~CCR8, a chemokine receptor ~~CCR8. CCR8 is~~ expressed on regulatory T cells, ~~(Treg)~~or Tregs, in the TME. SRF114 ~~is a highly-specific antibody that is designed to deplete these immuno-suppressive cells.~~

~~SRF231 is an antibody targeting CD47, a protein expressed on many cells that is often overexpressed on tumor cells. By targeting CD47,~~causes depletion of intra-tumoral Tregs, important regulators of immune suppression and tolerance, through antibody-dependent cellular cytotoxicity, or ADCC. In March 2021, we ~~believe we can promote macrophage activation to attack such tumors. We~~ initiated a Phase 1 clinical trial of SRF231 in February 2018. In December 2018, we announced the deprioritization of SRF231 as a result of toxicities seen during the dose escalation portion of the ongoing Phase 1 trial and the evolving competitive landscape. We expect to conclude the Phase 1 trial in 2020, and do not plan to further develop SRF231.IND-enabling activities for SRF114.

We expect that the unique insights generated in any one of our product programs will accelerate the development of the other programs in a synergistic fashion due to the interconnections between these TME pathways.

2322

Table of Contents

We were incorporated and commenced principal operations in 2014. We have devoted substantially all of our resources to developing our programs, including NZV930, SRF617, SRF388, SRF813, and ~~SRF231,~~SRF114, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations with proceeds from the public and private sales of our securities, payments received under the ~~Collaboration~~Novartis Agreement, ~~with Novartis~~payments received under the GSK Agreement and a debt financing. As of June 30, ~~2020,~~2021, we had cash, cash equivalents and marketable securities of ~~$112.5~~$164.3 million. Since our inception, we have incurred significant losses. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of the product candidates we develop. Our net ~~income~~loss was ~~$7.8~~$19.0 million and $34.5 million for the three and six months ended June 30, ~~2020.~~2021, respectively. Our net loss was $14.8 million for the three months ended June 30, 2020 and ~~$17.8 and $22.0~~our net income was $7.8 million for the ~~three and~~ six months ended June 30, ~~2019,~~2020, respectively. As of June 30, ~~2020,~~2021, we had an accumulated deficit of ~~$113.8~~$96.8 million. We expect to continue to incur significant expenses and operating losses for at least the next several years, particularly as we:

•pursue the clinical development of product candidates;

•leverage our programs to advance product candidates into preclinical and clinical development;

•seek regulatory approvals for any product candidates that successfully complete clinical trials;

•hire additional clinical, quality control, and scientific personnel;

•expand our operational, financial, and management systems and increase personnel, including personnel to support our clinical development, manufacturing, and commercialization efforts, and our operations as a public company;

•maintain, expand and protect our intellectual property portfolio;

•establish a sales, marketing, medical affairs, and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with a commercial partner; and

•acquire or in-license other product candidates and technologies.

As a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. We may be unable to raise additional funds or enter into other agreements or arrangements, when needed, on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates.

Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

We believe that our existing cash, cash equivalents and marketable securities, as of June 30, ~~2020~~2021 will enable us to fund our operating expenses, debt service obligations and capital expenditure requirements into ~~2022,~~2023, excluding any future milestone payments from ~~Novartis.~~Novartis and GSK. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.

We are monitoring the ongoing global outbreak and spread of the novel ~~strain of~~ coronavirus disease, or COVID-19, and have taken steps to identify and mitigate the adverse impacts on, and risks to, our business posed by its spread and actions taken by governmental and health authorities to address the COVID-19 pandemic. Although COVID-19 has not yet had a material adverse impact on our operations and our clinical and preclinical programs, the spread of COVID-19 has caused us to modify our business practices, including implementing a work from home policy for all employees who are able to perform their duties remotely and restricting all nonessential travel, and we expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees, and other business partners in light of COVID-19. Given the fluidity of the COVID-19 pandemic however, we do not yet know the full extent of the potential impact of COVID-19 on our business operations. We will continue to monitor the situation closely.

2423

Table of Contents

Components of Our Results of Operations

Revenue

To date, we have not generated any revenue from product sales and do not expect to do so in the near future. All of our revenue to date has been derived from the ~~Collaboration~~Novartis Agreement and the GSK Agreement. If our development efforts for our programs are successful and result in regulatory approval or additional license or collaboration agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from additional collaboration or license agreements that we may enter into with third parties. We expect that our revenue for the next several years will be derived primarily from ~~future milestone payments under~~ the ~~Collaboration~~Novartis Agreement and the GSK Agreement, as well as any additional collaborations or licenses that we may enter into in the future.

~~Collaboration~~Novartis Agreement ~~with Novartis~~

In January 2016, we entered into the ~~Collaboration~~Novartis Agreement to develop next-generation cancer therapies. Under the ~~Collaboration~~Novartis Agreement, as amended, we were responsible for performing research on antibodies that bind to CD73 and four other specified targets. We were responsible for all costs and expenses incurred by, or on behalf of, us in connection with the research.

Upon entering into the agreement, we received an upfront payment of $70.0 million from Novartis and granted Novartis a worldwide exclusive license to research, develop, manufacture and commercialize antibodies that target CD73. In addition, we initially granted Novartis the right to purchase exclusive option rights, each an Option, to up to four specified targets, including certain research, development, manufacturing and commercialization rights. Pursuant to the ~~Collaboration~~Novartis Agreement, Novartis initially had the right to exercise up to three purchased Options. In March 2018, Novartis notified us of its decision to not exercise its previously purchased Option for SRF231, our CD47 product candidate. In March 2018, we and Novartis also mutually agreed to cease development of one of the undisclosed programs subject to the Collaboration Agreement. In February 2019, Novartis notified us of its decision not to purchase its Option related to IL-27. In January 2020, Novartis did not purchase and exercise its single remaining Option under the ~~Collaboration~~Novartis Agreement and, as a result, the option purchase period expired. Accordingly, there are no Options remaining eligible for purchase and exercise by Novartis, and our performance obligations under the ~~Collaboration~~Novartis Agreement have ended. We are currently entitled to potential development milestones of ~~$525.0~~$325.0 million, potential sales milestones of $200.0 million, as well as tiered royalties on annual net sales of NZV930 by Novartis ranging from high single-digit to mid-teens percentages. Such amount of potential milestone payments assumes the successful clinical development and achievement of all sales milestones for NZV930.

Under ASC 606 we account for (i) the license conveyed with respect to CD73 and (ii) our obligations to perform research on CD73 and other specified targets as a single performance obligation under the ~~Collaboration~~Novartis Agreement. We recognize revenue using the cost-to-cost method, which we believe best depicts the transfer of control to the customer. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion.

Through June 30, ~~2020,~~2021, we had received an aggregate of $150.0 million from Novartis in upfront payments, milestone payments, and option purchase payments. As of January 2020, we no longer have any performance obligations under the ~~Collaboration~~Novartis Agreement. We removed all costs associated with the remaining performance obligation for the single remaining Option from the cost-to-cost model in January 2020. This resulted in our recognizing the remaining deferred revenue of $38.6 million to collaboration revenue – related party in the first quarter of 2020. ~~During~~We did not recognize any collaboration revenue - related party in the three and six months ended June 30, ~~2019~~2021.

GSK Agreement

In December 2020, we entered into the GSK Agreement, under which we granted GSK a worldwide, exclusive, sublicensable license to develop, manufacture and commercialize antibodies that target the antibody SRF813, targeting CD112R, also known as PVRIG, or the Licensed Antibodies. GSK will be responsible for the development, manufacturing and commercialization of the Licensed Antibodies and a joint development committee has been formed to facilitate information sharing between us and GSK. Under the terms of the GSK Agreement, GSK is obligated to use commercially reasonable efforts to develop and commercialize the Licensed Antibodies.

Under the terms of the agreement, GSK made a one-time upfront payment of $85.0 million and is required to make additional payments to us for supply services and transition services, estimated to be $4.5 million and $1.0 million, respectively. We are eligible to receive up to $90.0 million in clinical and $155.0 million in regulatory milestones. In addition, we may receive up to $485.0 million in sales milestone payments. We are also eligible to receive royalties on global net sales of any approved products based on the licensed antibodies, ranging in percentages from high single digits to mid-teens.

Table of Contents

Under ASC 606 we account for (i) the delivery of the worldwide, exclusive, sublicensable license to develop, manufacture and commercialize the Licensed Antibodies; (ii) supply of Licensed Antibodies until an Investigational New Drug application is accepted by a regulatory authority; and (iii) transition services until an Investigational New Drug application is accepted by a regulatory authority as separate and distinct performance obligations. We determined the transaction price under ASC 606 at the inception of the GSK Agreement to be $90.4 million, consisting of the upfront payment of $85.0 million plus $4.5 million for supply of the Licensed Antibodies and $1.0 million for the transition services. We recognized revenue for the license performance obligation at a point in time, that is upon transfer of the license to GSK. As control of the license was transferred on the effective date of December 16, 2020 and GSK could begin to use and benefit from the license, we recognized $85.0 million of license related revenue ~~of $0.1~~during the year ended December 31, 2020 under the GSK Agreement. We will recognize the $4.5 million and ~~$14.6~~$1.0 million ~~respectively, related~~allocated to the ~~Collaboration Agreement.~~supply services and transition services over time. We transfer control of these services over time and GSK receives and consumes the benefit over time as we perform the services. For the three and six months ended June 30, 2021, we recognized $0.3 million and $0.7 million of license related revenue, respectively, from transition services and $0.2 million and $1.5 million of license related revenue, respectively, from the supply services, which represents the costs incurred for the manufacturing and transition services that were performed.

Through June 30, 2021, we have received $85.0 million from GSK in upfront payments.

Operating Expenses

Research and Development Expenses

Research and development expenses are expensed as incurred and consist of costs incurred for our research activities, including our discovery efforts, and the development of our programs. These expenses include:

•salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions;

•expenses incurred in connection with the preclinical development of our programs and clinical trials of our product candidates, including under agreements with third parties, such as consultants, contractors, and contract research organizations, or CROs;

~~Table of Contents~~

•the cost of manufacturing drug products for use in our preclinical studies and clinical trials, including under agreements with third parties, such as consultants, contractors, and contract manufacturing organizations, or CMOs;

•laboratory supplies;

•facilities, depreciation and other expenses, which include direct and allocated expenses for depreciation and amortization, rent and maintenance of facilities, insurance and supplies; and

•third-party license fees.

We generally do not track our internal research and development expenses on a program-by-program basis as they primarily relate to personnel, early research and consumable costs, which are deployed across multiple projects under development. These costs are included in unallocated research and development expenses in the table below. A portion of our research and development costs are external costs, which we do track on a program-by-program basis.

Table of Contents

The following table summarizes our research and development expenses by program:


		Three months ended June 30,						Six months ended June 30,							Three months ended June 30,				Six months ended June 30,
		2020		2019		2020		2019			2021		2020		2021		2020

		(in thousands)																		(in thousands)
SRF231		$	203	$	1,777	$	105	$	4,327
SRF388	SRF388	2,160		1,794		2,918		3,879		SRF388	$	4,076	$	2,160	$	5,500	$	2,918
SRF617	SRF617	1,132		3,183		3,329		6,891		SRF617	2,523		1,132		4,269		3,329
SRF813	SRF813	955		183		2,659		348		SRF813	398		955		1,748		2,659
SRF114	SRF114	87		105		163		191		SRF114	386		87		1,272		163
Other early-stage programs	Other early-stage programs	518		406		547		567		Other early-stage programs	77		721		119		652
Unallocated research and discovery expenses	Unallocated research and discovery expenses	4,493		5,788		11,115		11,342		Unallocated research and discovery expenses	5,209		4,493		10,305		11,115
Total research and development expenses	Total research and development expenses	$	9,548	$	13,236	$	20,836	$	27,545	Total research and development expenses	$	12,669	$	9,548	$	23,213	$	20,836

Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We anticipate that our research and development expenses will increase in the future as we anticipate incurring increased clinical development costs as we advance our SRF617 and SRF388 Phase 1 clinical trials as well as increased costs relating to the ~~SRF813~~SRF114 program as we pursue ~~IND enabling~~IND-enabling activities. ~~In the six months ended June 30, 2020, we recognized $1.2 million in severance expense as a result of the strategic restructuring in January 2020.~~

At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of any of our product candidates that we develop from our programs. We are also unable to predict when, if ever, net cash inflows will commence from sales of product candidates we develop. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:

•successful completion of clinical trials and preclinical studies;

•sufficiency of our financial and other resources to complete the necessary clinical trials and preclinical studies;

•acceptance of INDs for our planned clinical trials or future clinical trials;

•successful enrollment and completion of clinical trials;

•successful data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended populations;

•receipt of regulatory and marketing approvals from applicable regulatory authorities;

•receipt and maintenance of marketing approvals from applicable regulatory authorities;

•establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved;

•entry into collaborations to further the development of our product candidates;

~~Table of Contents~~

•obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;

•successfully launching commercial sales of our product candidates, if and when approved;

•acceptance of our product candidates’ benefits and uses, if and when approved, by patients, the medical community and third-party payors;

•maintaining a continued acceptable safety profile of the product candidates following approval;

•effectively competing with other therapies; and

•obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors.

A change in the outcome of any of these variables with respect to the development of any of our programs or any product candidate we develop would significantly change the costs, timing, and viability associated with the development of such program or product candidate.

Table of Contents

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and personnel-related costs, including stock-based compensation, for our personnel in executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees paid for accounting, auditing, consulting and tax services; insurance costs; travel expenses; and facility costs not otherwise included in research and development expenses.

We anticipate that our general and administrative expenses will ~~decrease~~increase in the future as a result of ~~the strategic restructuring and reduction in force announced in January 2020, however, we still anticipate~~ incurring increased accounting, audit, legal, regulatory, compliance, and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company.

Interest and Other Income (Expense), Net

Interest and other income consist primarily of interest earned on our cash, cash equivalents, and marketable ~~securities.~~securities as well as interest expense incurred on our Loan Agreement with K2HV.

Results of Operations

Comparison of Three Months Ended June 30, ~~2020~~2021 and ~~2019~~2020

The following table summarizes our results of operations for the three months ended June 30, ~~2020~~2021 and ~~2019,~~2020, along with the changes in those items:


	Three months ended June 30,
	2021		2020		2021 v 2020
	(in thousands)
License related revenue	$	515	$	—	$	515
Operating expenses:
Research and development	12,669		9,548		3,121
General and administrative	6,434		4,995		1,439
Total operating expenses	19,103		14,543		4,560
Loss from operations	(18,588)		(14,543)		(4,045)
Interest and other income (expense), net	(393)		(264)		(129)
Net loss	$	(18,981)	$	(14,807)	$	(4,174)

Three months ended June 30,
2020 2019 2020 v 2019
(in thousands)
Collaboration revenue - related party $ — $ 143 $ (143)
Operating expenses:
Research and development 9,548 13,236 (3,688)
General and administrative 4,995 5,417 (422)
Total operating expenses 14,543 18,653 (4,110)
Loss from operations (14,543) (18,510) 3,967
Interest and other income (expense), net (264) 752 (1,016)
Net loss $ (14,807) $ (17,758) $ 2,951

~~Collaboration~~License Related Revenue

~~In January 2020, our performance obligations under~~During the ~~Collaboration Agreement~~three months ended June 30, 2021, we recognized $0.3 million and ~~we removed all~~$0.2 million of license related revenue related to the transition services and supply services, respectively, which represents the costs ~~from~~incurred for the ~~cost-to-cost model.Therefore, we~~manufacturing and transition services that were performed. We did not ~~record~~recognize any ~~collaboration~~license related revenue in the three months ended June 30, 2020. ~~Collaboration revenue was $0.1 million for the three months ended June 30, 2019, all of which was derived from the Collaboration Agreement.~~

Table of Contents

Research and Development Expenses

The following table summarizes our research and development expenses for the three months ended June 30, ~~2020~~2021 and ~~2019,~~2020, along with the changes in those items:


	Three months ended June 30,
	2021		2020		2021 v 2020
	(in thousands)
Direct research and development expenses by program:
SRF388	$	4,076	$	2,160	$	1,916
SRF617	2,523		1,132		1,391
SRF813	398		955		(557)
SRF114	386		87		299
Other early-stage programs	77		721		(644)
Research and discovery and unallocated expenses:
Personnel related (including stock-based compensation)	3,463		3,411		52
Facility related and other	1,746		1,082		664
Total research and development expenses	$	12,669	$	9,548	$	3,121

Three months ended June 30,
2020 2019 2020 v 2019
(in thousands)
Direct research and development expenses by program:
SRF231 $ 203 $ 1,777 $ (1,574)
SRF388 2,160 1,794 366
SRF617 1,132 3,183 (2,051)
SRF813 955 183 772
SRF114 87 105 (18)
Other early-stage programs 518 406 112
Research and discovery and unallocated expenses:
Personnel related (including stock-based compensation) 3,411 4,168 (757)
Facility related and other 1,082 1,620 (538)
Total research and development expenses $ 9,548 $ 13,236 $ (3,688)

Research and development expenses were $12.7 million for the three months ended June 30, 2021, compared to $9.5 million for the three months ended June 30, ~~2020, compared to $13.2 million for the three months ended June 30, 2019.~~2020. The ~~decrease~~increase of ~~$3.7~~$3.1 million was primarily due to ~~decreases~~increases of ~~$1.6~~$1.9 million in external costs for our ~~SRF231~~SRF388 program, ~~$2.1~~$1.4 million in external costs for our SRF617 program, $0.3 million in external costs for our SRF114 program, and ~~$1.3~~$0.7 million for research and discovery and unallocated costs, ~~which was~~ partially offset by ~~increases~~decreases of ~~$0.4 million in external costs for our SRF388 program, $0.8~~$0.6 million in external costs for our SRF813 program and ~~$0.1~~$0.6 million in ~~our early-stage programs.~~

~~The decrease in research and development expenses~~external costs for our SRF231 program was primarily due to the deprioritization of SRF231 program, which we announced in December 2018, and the conclusion of the Phase 1 clinical trial, which we anticipate will occur in 2020.

~~The decrease in research and development expenses for our SRF617 program was primarily due to a decrease in contract manufacturing work and~~ other ~~IND enabling activities which primarily occurred in 2019. This was partially offset by progression of the Phase 1 clinical trial in the second quarter of 2020.~~

~~The decrease in research and discovery and unallocated expenses was primarily due to the reduction in headcount as a result of the strategic restructuring announced in January 2020.~~early stage programs.

The increase in research and development expenses for our SRF388 program was primarily due to acontinued enrollment in our Phase 1 dose escalation trial and advancement into the ~~initial start-up costs and progression~~expansion stages of the ongoing trial in 2021.

The increase in research and development expenses for our SRF617 program was primarily due to continued enrollment in our Phase ~~1 clinical~~1/1b dose escalation trial and advancement into combination cohorts of the ongoing trial in 2021.

The increase in research and development expenses for our SRF114 program was primarily due to the initiation of IND-enabling activities in 2021.

The increase in research and discovery and unallocated expenses was primarily due to an increase in headcount in 2021 as well as increased facility and lab costs in second quarter of 2021 compared to these second quarter of 2020 as a result of reduced presence in the office due to safety concerns arising the COVID-19 global pandemic in the second quarter of ~~2020, which was partially offset by a decrease in contract manufacturing work and other IND enabling activities which primarily occurred in 2019.~~2020.

The ~~increase~~decrease in research and development expenses for our SRF813 program was primarily due to ~~increased contract manufacturing work and other IND enabling activities incurred~~the transfer of responsibility for development of this program to ~~advance~~GSK as part of the ~~program~~GSK Agreement signed in December 2020.

General and Administrative Expenses

General and administrative expenses were $6.4 million for the three months ended June 30, 2021, compared to $5.0 million for the three months ended June 30, ~~2020, compared to $5.4 million for the three months ended June 30, 2019.~~2020. The ~~decrease~~increase of ~~$0.4~~$1.4 million was primarily due to ~~decreases~~increases in personnel and facility related ~~costs as well as a reduction legal fees.~~costs.

Interest and Other Income (Expense), Net

Interest and other income (expense), net were approximately ~~$(0.3)~~$(0.4) million and ~~$0.8~~$(0.3) million during the three months ended June 30, ~~2020~~2021 and ~~2019,~~2020, respectively, due primarily to interest expense related to the Loan Agreement with K2HV and interest income on invested balances of our cash, cash equivalents and marketable securities.

Table of Contents

Comparison of Six Months Ended June 30, ~~2020~~2021 and ~~2019~~2020

The following table summarizes our results of operations for the six months ended June 30, ~~2020~~2021 and ~~2019,~~2020, along with the changes in those items:


		Six months ended June 30,									Six months ended June 30,
		2020		2019		2020 v 2019			2021		2020		2021 v 2020
				(in thousands)							(in thousands)
Collaboration revenue - related party	Collaboration revenue - related party	$	38,592	$	14,577	$	24,015	Collaboration revenue - related party	$	—	$	38,592	$	(38,592)
License related revenue								License related revenue	2,141		—		2,141
Total revenue								Total revenue	$	2,141	$	38,592	$	(36,451)
Operating expenses:	Operating expenses:							Operating expenses:
Research and development	Research and development	20,836		27,545		(6,709)		Research and development	23,213		20,836		2,377
General and administrative	General and administrative	9,782		10,510		(728)		General and administrative	12,076		9,782		2,294
Total operating expenses	Total operating expenses	30,618		38,055		(7,437)		Total operating expenses	35,289		30,618		4,671
Income (loss) from operations	Income (loss) from operations	7,974		(23,478)		31,452		Income (loss) from operations	(33,148)		7,974		(41,122)
Interest and other income, net		(211)		1,521		(1,732)
Interest and other income (expense), net								Interest and other income (expense), net	(1,394)		(211)		(1,183)
Net income (loss)	Net income (loss)	$	7,763	$	(21,957)	$	29,720	Net income (loss)	$	(34,542)	$	7,763	$	(42,305)

Collaboration Revenue - Related Party

Collaboration revenue was $38.6 ~~million and $14.6~~ million for the six months ended June 30, 2020, ~~and 2019, respectively,~~ all of which was derived from the ~~Collaboration~~Novartis Agreement. In January 2020 our performance obligations under the ~~Collaboration~~Novartis Agreement ended and we removed all costs from the cost-to-cost model. This resulted in the recognition of the remaining deferred revenue of $38.6 million to collaboration revenue – related party in the first quarter of 2020. We did not recognize any collaboration revenue - related party in the six months ended June 30, 2021.

License Related Revenue

During the six months ended June 30, 2021, we recognized $1.5 million and $0.7 million of license related revenue related to the supply services and transition services, respectively, which represents the costs incurred for the manufacturing and transition services that were performed. We did not recognize any license related revenue in the six months ended June 30, 2020.

Research and Development Expenses

The following table summarizes our research and development expenses for the six months ended June 30, ~~2020~~2021 and ~~2019,~~2020, along with the changes in those items:


		Six months ended June 30,									Six months ended June 30,
		2020		2019		2020 v 2019			2021		2020		2021 v 2020
				(in thousands)							(in thousands)
Direct research and development expenses by program:	Direct research and development expenses by program:							Direct research and development expenses by program:
SRF231		$	105	$	4,327	$	(4,222)
SRF388	SRF388	2,918		3,879		(961)		SRF388	$	5,500	$	2,918	$	2,582
SRF617	SRF617	3,329		6,891		(3,562)		SRF617	4,269		3,329		940
SRF813	SRF813	2,659		348		2,310		SRF813	1,748		2,659		(911)
SRF114	SRF114	163		191		(28)		SRF114	1,272		163		1,109
Other early-stage programs	Other early-stage programs	547		567		(20)		Other early-stage programs	119		652		(533)
Research and discovery and unallocated expenses:	Research and discovery and unallocated expenses:							Research and discovery and unallocated expenses:
Personnel related (including stock-based compensation)	Personnel related (including stock-based compensation)	8,171		8,043		128		Personnel related (including stock-based compensation)	6,945		8,171		(1,226)
Facility related and other	Facility related and other	2,944		3,299		(355)		Facility related and other	3,360		2,944		416
Total research and development expenses	Total research and development expenses	$	20,836	$	27,545	$	(6,710)	Total research and development expenses	$	23,213	$	20,836	$	2,377

Research and development expenses were $20.8 million for the six months ended June 30, 2020, compared to $27.5 million for the six months ended June 30, 2019. The decrease of $6.7 million was primarily due to decreases of $4.2 million in external costs for our SRF231 program, $1.0 million in external costs for our SRF388 program, $3.6 million in external costs for our SRF617 program, and $0.2 million for research and discovery and unallocated costs, which was partially offset by an increase of $2.3 million in external costs for our SRF813 program.

The decrease in research and development expenses for our SRF231 program was primarily due to the deprioritization of SRF231 program, which we announced in December 2018, and the conclusion of the Phase 1 clinical trial, which we anticipate will occur in 2020. Additionally, we received a refund of $0.7 million in the first quarter of 2020 relating to materials purchased in 2018.

Table of Contents

Research and development expenses were $23.2 million for the six months ended June 30, 2021, compared to $20.8 million for the six months ended June 30, 2020. The ~~decrease~~increase of $2.4 million was primarily due to increases of $2.6 million in external costs for our SRF388 program, $0.9 million in external costs for our SRF617 program and $1.1 million in external costs for our SRF114 program, which were partially offset by decreases of $0.8 million for research and discovery and unallocated costs and $0.9 million in external costs for our SRF813 program

The increase in research and development expenses for our SRF388 program was primarily due to continued enrollment in our Phase 1 dose escalation trial and advancement into the expansion stages of the ongoing trial in 2021.

The increase in research and development expenses for our SRF617 program was primarily due to ~~a decrease~~continued enrollment in ~~contract manufacturing work~~our Phase 1/1b doss escalation trial and ~~other IND enabling activities which primarily occurred~~advancement into combination cohorts of the ongoing trial in ~~2019. This was partially offset by the progression in the Phase 1 clinical trial throughout 2020.~~2021.

The ~~decrease~~increase in research and development expenses for our ~~SRF388~~SRF114 program was primarily due to ~~a decrease in contract manufacturing work and other IND enabling~~the initiation of IND-enabling activities ~~which primarily occurred in 2019. This was partially offset by the progression~~ in the ~~Phase 1 clinical trial throughout 2020.~~first quarter of 2021.

The decrease in research and discovery and unallocated expenses was primarily due to the reduction in ~~headcount~~severance expense incurred in 2020 as a result of the strategic restructuring announced in January 2020.

The ~~increase~~decrease in research and development expenses for our SRF813 program was primarily due to ~~increased contract manufacturing work and other IND enabling activities incurred to advance~~the transfer of responsibility for development of the program to GSK as part of the GSK Agreement signed in December 2020.

General and Administrative Expenses

General and administrative expenses were $12.1 million for the six months ended June 30, 2021, compared to $9.8 million for the six months ended June 30, ~~2020, compared to $10.5 million for the six months ended June 30, 2019.~~2020. The ~~decrease~~increase of ~~$0.7~~$2.3 million was primarily due to ~~decreases~~increases in personnel and facility related costs, ~~as well as a reduction~~including $0.4 million of stock-based compensation resulting from modifications to previously issued stock option awards in ~~legal fees.~~connection with the transition of our Chief Executive Officer to Chairman of the Board.

Interest and Other Income (Expense), Net

Interest and other income (expense), net were approximately ~~$(0.2)~~$(1.4) million and ~~$1.5~~$(0.2) million during the six months ended June 30, ~~2020~~2021 and ~~2019,~~2020, respectively, due primarily to interest expense related to the Loan Agreement with K2HV and interest income on invested balances of our cash, cash equivalents and marketable securities.

Liquidity and Capital Resources

Since our inception, we have incurred significant operating losses. We have generated limited revenue to date from the ~~Collaboration~~Novartis Agreement and the GSK Agreement. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. To date, we have financed our operations with proceeds from public and private sales of our securities, payments received under the ~~Collaboration~~Novartis Agreement, payments received under the GSK Agreement and a debt financing. Through June 30, ~~2020,~~2021, we had received gross proceeds of $48.6 million from our sales of preferred stock, $29.1 million from sales of our common stock under the 2019 Sales Agreement, $19.0 million from sales of our common stock under the 2020 Sales Agreement, $17.5 million from our ~~loan and security agreement~~Loan Agreement with ~~K2 HealthVentures LLC~~K2HV, $85.0 million from the GSK Agreement and $150.0 million from the ~~Collaboration~~Novartis Agreement.

On April 23, 2018, we completed an initial public offering of our common stock by issuing 7,200,000 shares of common stock, at $15.00 per share for gross proceeds of $108.0 million, or net proceeds of $97.2 million. Concurrent with the initial public offering, we issued Novartis 766,666 shares of our common stock at $15.00 per share, for proceeds of $11.5 million, in a private placement.

In May 2019, we entered into ~~a Capital on Demand~~™ ~~Sales Agreement, or~~ the 2019 Sales Agreement, with JonesTrading ~~Institutional Services~~ to issue and sell up to $30.0 million in shares of our common stock, from time to time. ~~Through~~As of June 30, 2020, we sold 11,229,174 shares of common stock at-the-market under the 2019 Sales Agreement for net proceeds of $29.1 ~~million. As of June 30, 2020, the Company has~~million, and had fully utilized and closed the 2019 ATM Facility.

In May 2020, we entered into ~~a Capital on Demand~~™ ~~Sales Agreement, or~~ the 2020 Sales Agreement, with JonesTrading ~~Institutional Services~~ to issue and sell up to $50.0 million in shares of our common stock, from time to time. Through June 30, ~~2020,~~2021, we ~~have not~~ sold ~~any~~2,233,760 shares of common stock at-the-market under the 2020 Sales ~~Agreement.~~Agreement for net proceeds of $19.0 million.

Table of Contents

As of June 30, ~~2020,~~2021, we had cash, cash equivalents and marketable securities of ~~$112.5~~$164.3 million.

Future Funding Requirements

We expect our expenses will increase in the future as we anticipate incurring increased clinical development costs as we advance our SRF617 and SRF388 Phase 1 clinical trials as well as increased costs relating to the ~~SRF813~~SRF114 program as we pursue ~~IND enabling~~IND-enabling activities. Additionally, we expect to continue to incur additional costs associated with operating as a public company.

~~Table of Contents~~

We believe that our existing cash, cash equivalents, and marketable securities, as of August ~~11, 2020,~~5, 2021, will enable us to fund our operating expenses, debt service obligations and capital expenditure requirements into ~~2022,~~2023, excluding any future milestone payments from ~~Novartis.~~Novartis and GSK. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect.

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:

•completing clinical development of existing product candidates and programs, identifying new product candidates, and completing pre-clinical and clinical development of such product candidates;

•seeking and obtaining marketing approvals for any of product candidates that we develop;

•launching and commercializing product candidates for which we obtain marketing approval by establishing a sales force, marketing, medical affairs and distribution infrastructure or, alternatively, collaborating with a commercialization partner;

•achieving adequate coverage and reimbursement by hospitals, government and third-party payors for product candidates that we develop;

•establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and the market demand for product candidates that we develop, if approved;

•obtaining market acceptance of product candidates that we develop as viable treatment options;

•addressing any competing technological and market developments;

•negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations in such collaborations;

•maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;

•defending against third-party interference or infringement claims, if any; and

•attracting, hiring and retaining qualified personnel.

A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.

In addition to the variables described above, if and when any product candidate we develop successfully completes development, we will incur substantial additional costs associated with regulatory filings, marketing approval, post-marketing requirements, maintaining our intellectual property rights, and regulatory protection, in addition to other costs. We cannot reasonably estimate these costs at this time.

Table of Contents

Until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements, including the ~~Collaboration~~Novartis Agreement and the GSK Agreement. To the extent that we raise additional capital through the future sale of equity or debt, the ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We may require additional capital beyond our currently anticipated amounts. Additional capital may not be available on reasonable terms, or at all. If we raise additional funds through collaboration arrangements in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate development or future commercialization efforts.

~~Table of Contents~~

Cash Flows

The following table summarizes information regarding our cash flows for each of the periods presented:


		Six months ended June 30,							Six months ended June 30,
		2020		2019			2021		2020
		(in thousands)							(in thousands)
Net cash provided by (used in):	Net cash provided by (used in):					Net cash provided by (used in):
Operating activities	Operating activities	$	(32,048)	$	(32,409)	Operating activities	$	(31,229)	$	(32,048)
Investing activities	Investing activities	38,977		(12,996)		Investing activities	(81,311)		38,977
Financing activities	Financing activities	39,441		244		Financing activities	20,734		39,441
Net increase (decrease) in cash and cash equivalents and restricted cash	Net increase (decrease) in cash and cash equivalents and restricted cash	$	46,370	$	(45,161)	Net increase (decrease) in cash and cash equivalents and restricted cash	$	(91,806)	$	46,370

Operating Activities

During the six months ended June 30, 2021, net cash used in operating activities was $31.2 million, primarily due to a net loss of $34.5 million and changes in our operating assets and liabilities of $4.3 million, partially offset by non-cash charges of $7.6 million. Net cash used in changes in our operating assets and liabilities for the six months ended June 30, 2021 consisted primarily of a $1.7 million decrease in accrued expenses and other current liabilities, a $0.5 million decrease in accounts payable, and an increase of $1.1 million in prepaid expenses and other current assets. The decrease in accrued expenses and other current liabilities is primarily due to the decrease in accrued severance and contact manufacturing costs. The increase in prepaid expenses and other current assets is primarily due to receivables from GSK related to reimbursement for the supply and transition services performed.

During the six months ended June 30, 2020, net cash used in operating activities was $32.0 million, primarily due changes in our operating assets and liabilities of $45.9 million, partially offset by net income of $7.8 million and non-cash charges of $6.1 million. Net cash used in changes in our operating assets and liabilities for the six months ended June 30, 2020 consisted primarily of a $38.6 million decrease in deferred revenue-related party, a $2.9 million decrease in accrued expenses and other current liabilities, a $2.9 million decrease in accounts payable, a $1.1 million increase in other liabilities, and an increase of $2.3 million in prepaid expenses and other current assets. The decrease in deferred revenue-related party was primarily due to the removal of all future costs in the cost-to-cost model as a result of Novartis’ decision not to purchase and exercise the single remaining Option under the Collaboration Agreement prior to it expiring in January 2020. The increase in other liabilities represents a commercial option fee which we incurred under the Adimab agreement in January 2020, but is not payable within twelve months of the balance sheet date. The decrease in accounts payable and accrued expenses is a result of the strategic restructuring announced in January 2020.

Investing Activities

During the six months ended June 30, ~~2019,~~2021, net cash used in ~~operating~~investing activities was ~~$32.4~~$81.3 million primarily due to a net loss of $22.0 million and changes in our operating assets and liabilities of $14.3 million, partially offset by non-cash charges of $3.9 million. Net cash used in operating assets and liabilities for the six months ended June 30, 2019 consisted primarily of a $14.6 million decrease in deferred revenue-related party, a $0.8 million decrease in accrued expenses and other current liabilities, a $0.9 million decrease in accounts payable, a $0.6 million decrease in operating lease liabilities, and a decrease of $2.5 million in prepaid expenses and other current assets. The decrease in deferred revenue-related party was primarily due to the removal of all future costs associated with IL-27 from the estimated total costs in the cost-to-cost model as a result of Novartis’ decision not to purchase the Option related to IL-27. The decrease in accrued expenses and other current liabilities was primarily due to a $1.1 million accrual for a commercial option fee license with Adimab in June 2018. The decrease in operating lease liabilities relates to lease payments made in the current year.

~~Investing Activities~~purchases of marketable securities.

During the six months ended June 30, 2020, net cash provided by investing activities was $39.0 million, primarily due to by $39.7 million of proceeds from sales or maturities of marketable securities partially offset by purchases of marketable securities of $0.7 million.

Table of Contents

Financing Activities

During the six months ended June 30, ~~2019,~~2021, net cash ~~used in investing~~provided by financing activities was ~~$13.0~~$20.7 million, ~~primarily due to purchases of marketable securities of $93.5 million and $1.1 million of purchases of property and equipment, partially offset by $81.6 million~~consisting of proceeds of $19.0 million received from ~~sales or maturities~~issuance of ~~marketable securities.~~

~~Financing Activities~~our shares of common stock at-the-market under the 2020 Sales Agreement, proceeds of $0.1 million received from the issuance of shares under our 2018 Employee Stock Purchase Plan, and proceeds from the exercise of stock options of $1.6 million.

During the six months ended June 30, 2020, net cash provided by financing activities was $39.4 million, consisting of proceeds of $29.1 million received from issuance of our shares of common stock at-the-market under the 2019 Sales Agreement, proceeds from the issuance of the second tranche of our convertible note payable of $10.0 million, and proceeds ~~form~~from the exercise of options to purchase common stock of $0.3 ~~million~~

~~During the six months ended June 30, 2019, net cash provided by financing activities was $0.2 million, consisting of proceeds received from the exercise of stock options.~~

~~Table of Contents~~

million.

Contractual Obligations

We have entered into agreements in the normal course of business with CROs for clinical trials and clinical supply manufacturing and with vendors for preclinical research studies and other services and products for operating purposes. These contractual obligations are ~~cancelable at any time~~generally cancellable by us ~~generally~~ upon prior written notice to the vendor.

During the six months ended June 30, ~~2020,~~2021, there were no material changes, to our contractual obligations and commitments from those described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Contractual Obligations and Commitments” in our Annual Report on Form 10-K filed with the SEC on March ~~10, 2020.~~9, 2021.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with the rules and regulations of the SEC, and generally accepted accounting principles in the United States, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as revenue and expenses during the reporting period. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.

Our critical accounting policies and the methodologies and assumptions we apply under them have not materially changed since our Annual Report on Form 10-K filed with the SEC on March ~~10, 2020, except for our adoption of the new leasing standard which is discussed above.~~9, 2021.

Off-Balance Sheet Arrangements

We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.

Recently Issued Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q.

Emerging Growth Company Status

As an “emerging growth company,” the Jumpstart Our Business Startups Act of 2012 allows us to delay adoption of new or revised accounting standards applicable to public companies until such standards are made applicable to private companies. However, we have irrevocably elected not to avail ourselves of this extended transition period for complying with new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our cash, cash equivalents and marketable securities as of June 30, ~~2020~~2021 consisted of cash, a money market fund invested primarily in short-term U.S. Treasury obligations and U.S. government agency bonds. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, we do not believe that we have any material exposure to changes in the fair value of our investment portfolio as a result of changes in interest rates.

~~Table of Contents~~

Item 4. Controls and Procedures

Limitations on Effectiveness of Controls and Procedures

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934). Based on that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, ~~2020.~~2021.

Changes in Internal Control Over Financial Reporting

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) has occurred during the three months ended June 30, ~~2020~~2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

In ~~January 2017,~~October 2020, we filed an opposition in the European Patent Office, or EPO, opposing the grant of European Patent No. EP ~~2242512~~3258951B1 to ~~Stanford University,~~Compugen, Ltd., or the ~~Stanford~~Compugen Patent. We ~~were~~are one of ~~seven~~two parties opposing the grant of the ~~Stanford~~Compugen Patent, which relates generally to ~~CD47~~PVRIG (an alternate name for CD112R) antibodies for use in treating cancer. ~~Stanford filed a~~The proprietor’s response to the ~~seven oppositions and~~statements of opposition was filed on March 22, 2021; we are currently awaiting a summons to oral arguments were held in August 2018. The Opposition Division of the EPO maintained an amended version of the patent. As of August 11, 2020, we and three additional opponents, and Stanford, had submitted notices of appeal to the Opposition Division’s interlocutory decision to the Technical Board of Appeal of the EPO.proceedings. Accordingly, final resolution of the ~~oppositions~~opposition may be several years in the future.

In June 2021, we filed an opposition in the European Patent Office, or EPO, opposing the grant of European Patent No. EP 3153526B1 to INSERM (Institut National de la Santé et de la Recherche Médicale), or the INSERM Patent. We are one of four parties opposing the grant of the INSERM Patent, which relates generally to anti-CD39 antibodies which inhibits activity of regulatory T cells (Treg) for use in the treatment or prevention of cancers. We currently await the proprietor’s response to the statements of opposition and subsequently a summons to oral proceedings. Accordingly, final resolution of the opposition may be several years in the future.

From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.

Item 1A. Risk Factors

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A ("(“Risk ~~Factors"~~Factors”) of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2019 and the additional risk factors disclosed in Item 1A ("Risk Factors") of our Quarterly Report on Form 10-Q for the three months ended March 31,~~ 2020.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

~~None.~~On August 5, 2021, we entered into Amendment No. 1 to Capital on Demand™ Sales Agreement (the “Amendment”) with JonesTrading which, among other things, amends the 2020 Sales Agreement to allow for the issuance and sale of the lesser of (a) the dollar amount of shares of Common Stock registered on the applicable effective Registration Statement (as defined in the Amendment) pursuant to which the offering is being made, (b) the number of authorized but unissued shares of Common Stock, (c) the number or dollar amount of shares of Common Stock permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable) or (d) the number or dollar amount of shares of Common Stock for which we have filed a Prospectus Supplement (as defined in the Amendment) (such lesser amount, the “Placement Shares”), through Jones Trading as sales agent, from time to time during the term of the 2020 Sales Agreement (as amended by the Amendment, the “2021 ATM Facility”). We are not obligated to make any sales of Common Stock under the 2021 ATM Facility. The issuance and sale, if any, of the Placement Shares by us under the 2021 ATM Facility will be made pursuant to a registration statement on Form S-3 and prospectus related thereto, which authorizes an aggregate offering price of up to $80,000,000 under the 2021 ATM Facility, in each case, to be filed within two business days of the date of the Amendment.

We will continue to pay JonesTrading a commission of up to three percent (3.0%) of the gross sales proceeds of any Placement Shares sold through JonesTrading under the 2021 ATM Facility. In connection with the Amendment, we have agreed to reimburse certain legal expenses and fees by JonesTrading in connection with the 2021 ATM Facility up to a maximum of $35,000.

Table of Contents

The foregoing description of the Amendment is not complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed herewith as Exhibit 1.1 to this Quarterly Report on Form 10-Q and is incorporated herein by reference. A copy of the opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of the Placement Shares will be filed with the registration statement on Form S-3 within two business days of the date of the Amendment.

This Quarterly Report on Form 10-Q shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Item 6. Exhibits.

The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q.


Exhibit Number						Description
1.1						Amendment No. 1, dated as of August 5, 2021, to Capital on DemandTM Sales Agreement, dated as of May 22, 2020, by and between Surface Oncology, Inc. and JonesTrading Institutional Services LLC.
31.1						Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2						Certification of Principal Financial and Accounting Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
~~32.1~~32.1*						Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
~~32.2~~32.2*						Certification of Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS						XBRL Instance Document
101.SCH						XBRL Taxonomy Extension Schema Document
101.CAL						XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF						XBRL Taxonomy Extension Definition Linkbase Document
101.LAB						XBRL Taxonomy Extension Label Linkbase Document
101.PRE						XBRL Taxonomy Extension Presentation Linkbase Document


*			The certification furnished in Exhibit 32.1 and Exhibit 32.2 hereto is deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.

3637

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Surface Oncology, Inc.
Date: August ~~11, 2020~~5, 2021	By:	/s/ ~~J. Jeffrey Goater~~Robert W. Ross, M.D.
		~~J. Jeffrey Goater~~Robert W. Ross, M.D.
		Chief Executive Officer (Principal Executive Officer)
Date: August ~~11, 2020~~5, 2021	By:	/s/ Jessica Fees
		Jessica Fees
		~~Treasurer and Senior Vice President, Finance~~Chief Financial Officer
		(Principal Financial and Accounting Officer)

3738


	December 31, 2019		Additions		Deductions		June 30, 2020
Contract liabilities ⁽¹⁾
Total deferred revenue - related party	$	38,592	$	—	$	(38,592)	$	—


Lease Costs	Classification	Three months ended June 30, 2020		Three months ended June 30, 2019		Six months ended June 30, 2020			Six months ended June 30, 2019

Operating lease cost	R&D Expense	$	511	$	572	$	1,051		$	1,158
	G&A Expense	826		237		1,624			461
Variable lease costs⁽¹⁾	R&D Expense	117		169		315			341
	G&A Expense	254		70		553			136
Total lease cost		$	1,708	$	1,048	$	3,543		$	2,096
Weighted-average remaining lease term (in months)						115.43			121.60
Weighted-average discount rate						10.5		%	10.4		%


Year Ending December 31,
2020	$	1,705
2021	5,529
2022	5,385
2023	5,413
2024	5,533
Thereafter	31,521
Total future lease payments	55,086
Less: Interest	(20,597)
Present value of future lease payments (lease liability)	$	34,489


Year Ending December 31,
2020	$	4,802
2021	5,529
2022	5,385
2023	5,413
2024	5,533
Thereafter	31,827
	$	58,489